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Chapter 1
General introduction and aims of the thesis
Introduction
8 Chapter 1
Heart failure is one of the most prevalent diseases in the Western world, and 
may become epidemic this century1. Myocardial infarction (MI) and chronic
hypertension are two of the most important causes for heart failure, with MI 
accounting for approximately 62% of all heart failure cases2. The cost of treatment 
of acute MI alone was estimated at $140 billion in the United States in 20023. 
Fortunately, new therapies arise, resulting in a decreased incidence of heart failure 
after MI, and increased survival after the onset of heart failure 4,5. However, despite 
these new insights in the development and consequence of these diseases, we are 
still unable to prevent and treat them sufficiently. Therefore, research investigating 
the underlying causes of heart failure is necessary to improve efficacy and reduce 
costs of treatment.
After myocardial infarction and during hypertension, the heart adapts itself to 
the changed conditions, by altering its shape and size, collectively termed cardiac 
remodeling. For instance, during hypertension the heart is subjected to an 
increased workload, and will adapt itself to this condition by increasing myocyte 
size and its ventricular mass, a process called cardiac hypertrophy (figure 1a).  This 
adaptation initially maintains normal cardiac function, but eventually may lead 
to the development of heart failure. One of the most important determinants 
deciding whether a hypertrophic heart will fail is the amount of extracellular 
matrix deposition, cardiac fibrosis (figure 1b). Cardiac fibrosis is caused by a 
variety of factors, like fibroblast proliferation, and growth factor activation. It 
causes stiffening of the left ventricle, thereby disabling ventricular relaxation, 
which results in diastolic dysfunction. 
During myocardial infarction, part of the heart is subjected to an abrupt lack 
of perfusion, causing myocyte necrosis (figure 2). This results in a healing 
response, which initiates cardiac remodeling. Grossly, infarct healing consists 
of three overlapping phases, an inflammatory phase, a proliferative phase, and 
a maturation phase 6. The inflammatory phase is hallmarked by the influx of 
leukocytes to remove the dead myocytes. Leukocyte infiltration is followed by 
influx of other inflammatory cells, like macrophages, which also help to clear the 
infarct zone from dead cells. The onset of the proliferative phase of infarct healing 
is marked by new extracellular matrix deposition, especially by differentiated 
fibroblasts (myofibroblasts). The formed granulation tissue increases the tensile 
strength of the infarct, thereby preventing cardiac rupture 7. Finally, the cell-rich 
granulation tissue evolves into a mature, collagen-based scar, characterized by the 
disappearance of cells and collagen cross-linking.
To find new targets and gain new insights in the development and consequences of 
hypertension and MI, the use of genetically modified animals is widely appreciated. 
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Figure 1. A, Chronic hypertension induces 
thickening of the ventricular wall, called 
cardiac hypertrophy. (Copyright © 2007 
Nucleus Medical Art, Inc. All rights reserved. 
www.nucleusinc.com). B, Typical example 
of interstitial cardiac fibrosis during cardiac 
hypertrophy causing ventricular stiffness 
and, ultimately, cardiac dysfunction.
Gene-inactivated or knockout (KO) mice are mice that lack a certain gene, and 
are ideal models to study the role of the particular protein in cardiac remodeling 
during hypertension or after MI, provided that they survive embryogenesis. The 
use of these mice has increased our knowledge about cardiovascular diseases, 
and remains inevitable. Also, transgenic animals overexpressing a certain gene 
are used in cardiovascular research. One of these is the transgenic TGR(mRen2)27 
(Ren2) rat, which is used by our group to study hypertension-induced cardiac 
failure 8-10. The studies described in this thesis all use genetic engineering to 
answer the specific research questions, thereby providing essential in vivo data 
concerning the role of investigated proteins. 
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As mentioned above, cardiac remodeling is an adaptive response occurring after 
MI or hypertension. Many factors are involved in the process of cardiac remodeling, 
but two arise as key mediators: angiotensin II (AngII) and transforming growth 
factor ß1 (TGFß1). These factors are critically involved in the development of 
cardiac hypertrophy and regulation of infarct healing 11,12. AngII and TGFß1 form 
a signaling network to induce cardiac remodeling, with TGFß1 usually acting as 
the effector molecule of AngII induced changes 13. 
For instance, it has been shown that AngII-induced cardiac hypertrophy and 
fibrosis is dependent on effective TGFß1 signaling14. Blockade of AngII by 
angiotensin converting enzyme (ACE) inhibitors or angiotensin type 1 receptor 
(AT1R) antagonists partly prevents cardiac remodeling, and improves survival in 
patients with heart failure. Although AngII and TGFß1 are key players in cardiac 
remodeling, altering their activity does not totally prevent the development 
of heart failure. Therefore, it is necessary to find other mediators of cardiac 
remodeling. Among these, matricellular proteins are emerging as possible players 
15, with some of them able to modify TGFß1 actions 16,17. Most of the matricellular 
proteins are expressed at very low levels in the normal heart, but their expression 
reappears after injury, like MI, suggesting an important function in the injured 
heart. Matricellular proteins are non-structural proteins that play a role in local 
signaling, and thereby provide a form of messenger function to the matrix.
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Figure 2. A, Myocardial infarction is caused by a blocked blood supply due to an occluded coronary artery. (Copyright © 
FH OÖ F&E GmbH, www.forte.fh-hagenberg.at). B, Section of an infarcted mouse heart, indicating that lack of oxygen 
causes myocyte necrosis and thinning of the left ventricle. LVW indicates left ventricular wall; RVW, right ventricular 
wall; S, septum; I, infarct.
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 The goal of this thesis was to clarify the role of several signaling systems in cardiac 
remodeling, as caused by myocardial infarction or hypertension. The thesis focuses 
on signaling mediated via matricellular proteins, which are non-structural proteins 
that reside in the interstitial matrix, and regulate growth factor mechanisms. We 
also evaluated the role of signaling molecules by direct inhibition of growth factors 
like platelet-derived growth factor (PDGF). Chapter 2 summarizes then available 
literature regarding matricellular proteins and proposes the potential roles of 
a set of matricellular proteins during cardiac remodeling in the stressed heart. 
The following chapters will answer some of the questions raised in that initial 
review, concerning the functions of matricellular proteins in the injured heart. 
In chapter 3, the role of secreted protein acidic and rich in cysteine (SPARC) during 
infarct healing is described. SPARC expression after MI is necessary for the deposi-
tion of a mature collagen matrix, as indicated by the increased cardiac rupture 
and immature collagen fibers seen in SPARC null mice after MI. Additionally, we 
show that SPARC is vital for signaling inside the cell, as TGFß signaling is impaired 
in SPARC knockdown fibroblasts. 
Chapter 4 & 5 describe the role of syndecan-1 after MI and during hypertension. In 
concordance with SPARC KO mice, syndecan-1 KO mice display cardiac dysfunction 
after MI, with impaired collagen matrix formation. Interestingly, lack of syndecan-
1 seems to be protective during AngII-mediated hypertension, as shown by 
attenuated cardiac fibrosis and cardiac dysfunction in syndecan-1 null mice. 
Finally, in addition we also show the importance of growth factor signaling when 
addressed more directly. Where the previous matricellular proteins affect signaling 
and cardiac structure through often unknown mechanisms, chapter 6 describes 
the potential beneficial effects of directly inhibiting platelet-derived growth factor 
(PDGF) receptor ß signaling by imatinib. Directly affecting this signaling pathway 
during chronic hypertension also affects the cardiac matrix by inhibiting cardiac 
fibroblast proliferation and collagen production, which results in decreased 
cardiac fibrosis. This finding may have important therapeutic implications, since 
imatinib is already clinically used. The broader clinical implications of this research 
are illustrated in chapter 7. 
Together, this thesis indicates the importance of matricellular proteins and growth 
factor signaling in regulating cardiac remodeling in the chronically overloaded 
heart. The findings described in this thesis provide novel insight in the functions of 
matricellular proteins during cardiac remodeling. While at the outset of the thesis 
there was very little information on this class of proteins in the heart, our studies 
provided highly novel findings. Matricellular proteins turned out to be necessary 
Introduction
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proteins for a proper cardiac adaptation to stress. While already known for years, 
this is the first documentation of the importance of matricellular proteins in the 
heart. This work highlights these proteins as potential targets for therapeutic 
interventions, and for large-scale clinical investigations.
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Abstract
Matricellular proteins are extracellular matrix proteins that modulate cell-
matrix interactions and cell function, and do not seem to have a direct structural 
role. The family includes tenascin C (TN-C), tenascin X (TN-X), osteonectin, 
osteopontin, thrombospondin-1 (TSP1) and thrombospondin-2 (TSP2).  Expression 
of matricellular proteins is high during embryogenesis, but almost absent during 
normal postnatal life. Interestingly, it reappears in response to injury. 
Left ventricular remodeling is a complicated process that occurs in the stressed 
heart, and is still not completely understood. Several members of the matricellular 
protein family, like TN-C, osteopontin, and osteonectin are up-regulated after 
cardiac injury. Therefore, this group of proteins may have crucial functions in the 
heart coping with stress. This review will focus on the expression, regulation and 
function of these matricellular proteins, and will discuss the crucial functions that 
these proteins might exert during remodeling of the stressed heart.
Chapter 2
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1. Introduction
A well-organized extracellular matrix is necessary to maintain strength and 
organization of cardiac tissue and is involved in communication between different 
cardiac cells. The last decade we have witnessed increasing interest in a group of 
‘matrix’ proteins that modulate cell function but do not appear to have a direct 
structural role in the extracellular matrix (ECM) of the heart 1. These matrix proteins 
have been termed ‘matricellular’ proteins to highlight their role in modulating cell 
function. 
The current review will focus on the biological role of matricellular proteins in 
the heart, in particular tenascin C (TN-C), tenascin X (TN-X), thrombospondin-1 
(TSP1), thrombospondin-2 (TSP2), osteonectin (also known as SPARC or BM-40) 
and osteopontin (OPN).  
A common property of matricellular proteins is their high expression during 
embryogenesis, which strongly decreases after birth, when expression becomes 
low to absent during normal adult life. Their expression reappears at high levels 
during tumor growth and after tissue injury 1, indicating a role for these proteins 
in migration and proliferation of malignant and wound healing cells, and in 
remodeling of the extracellular matrix. Matricellular proteins may indeed regulate 
cellular function and matrix production by binding to their cellular receptors 1,2,
and by modulating expression and activity of growth factors, cytokines, and 
proteinases 1. A variety of knockout mice has been generated to study the role 
of these matricellular proteins. Surprisingly, all of the mouse models where 
these proteins have been deleted by gene targeting survive embryogenesis, 
suggesting redundancy of these proteins during embryonic development. These 
gene deficient mice only show a mild phenotype after birth, mainly consisting of 
some abnormalities of collagen formation, with resulting hyperflexibility of the 
skin as described in TN-X and TSP2 deficient mice 3, 4. Absence of matricellular 
proteins, however, resulted in striking abnormalities in wound healing and matrix 
remodeling after injury, clearly indicating that their re-expression after tissue 
injury is vital for normal tissue healing and remodeling 5-9.  
The current review will first shortly describe the overall expression and function 
of each matricellular protein. Subsequently, it will focus more extensively on their 
expression and possible function in the heart. 
Matricellular proteins in the heart
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2. Tenascin C & Tenascin-X
TN-C is the founding member of the extracellular matrix family of tenascins. 
Other family members are TN-R, TN-X, TN-Y and TN-W 10. Since only TN-C and TN-X 
are described as modulators of cell adhesion, migration and growth, the current 
review will focus on these two tenascins. 
TN-C is highly expressed during embryogenesis 11, whereas its expression is very 
low after birth. TN-C, however, reappears under pathological conditions, such as 
infection, vascular hypertension, myocardial infarction 12 or tumor formation 8, 10. 
TN-C possesses adhesive as well as counteradhesive activities, which depend 
on ECM and cell surface receptor binding. The counteradhesive effects of TN-C 
are termed “de-adhesion”, meaning the induction of a transition from a strong 
cell-ECM adherence to an intermediate cell-ECM adhesion, as described in some 
excellent reviews 2, 8, 10, 13. De-adhesion facilitates cell migration and tissue 
remodeling during wound healing. 
TN-X is also widely expressed during embryogenesis, but, in contrast to TN-C, its 
expression persists after birth 14, 15. Until now, several functions of TN-X have been 
proposed. TN-X blocked invasion and metastasis of tumor cells 16, 17, enhanced cell 
proliferation stimulated by VEGF family proteins 18, 19, and modulated collagen 
fibrillogenesis 3.  TN-X gene inactivation in mice caused a syndrome of cutaneous 
hyperflexibility of the skin 3, mimicking the Ehlers-Danlos syndrome in human, 
which may also be caused by a mutation in the TN-X gene 20.
2.1 Tenascin-C and Tenascin-X in the heart
TN-C was only detected in the chorda tendinae of papillary muscles of the normal 
adult myocardium 21. However, TN-C reappeared under pathological conditions, 
including myocarditis 22, myocardial infarction 12, 23, hibernating myocardium 
24, and during dilated cardiomyopathy 25. Its expression correlated with cardiac 
injury and inflammation, and level of TN-C expression has been proposed as 
a marker for the severity of viral myocarditis 22. After myocardial infarction, 
TN-C appeared at the borderzone between the infarcted area and the intact 
myocardium where extensive remodeling occurred 12.  TN-C may exert a dual role 
in cardiac healing after myocardial infarction. TN-C may loosen cardiomyocytes 
from the matrix, thereby causing slippage of cardiomyocytes, and facilitating 
invasion of inflammatory cells and capillaries after myocardial infarction. It 
may also increase matrix production, thereby strengthening the cardiac matrix. 
Loosening of the cardiomyocytes from the matrix may occur by TN-C mediated 
de-adhesion. In addition, TN-C upregulates the transcription and activity of matrix 
metalloproteinases (MMPs) 26, promoting degradation of the extracellular matrix, 
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and increasing the risk of cardiac dilatation and rupture after myocardial infarction 
27-29. Increased production of matrix, in contrast, may occur by TN-C mediated 
recruitment of myofibroblasts 12, which are the main cells involved in production 
of new collagen shortly after myocardial infarction 30. In addition, elastic properties 
of TN-C 31 may also help to resist the increased mechanical loading to which the 
borderzone of the infarct is subjected. Whether TN-C reappearance after cardiac 
injury is beneficial or detrimental remains unclear, considering the paradoxical 
functions of TN-C in matrix remodeling. Whereas TN-C mediated de-adhesion 32 
and increase in MMPs 26  might predispose to left ventricular dilatation, recruitment 
of myofibroblasts by TN-C and its elastic properties may strengthen the ventricle 
through accelerated fibrosis. The precise role of TN-C in matrix remodeling after 
cardiac injury or stress requires further investigation in mice lacking the TN-C gene. 
In contrast to TN-C, TN-X is expressed in the heart during embryogenesis and 
adulthood, which implies a vital function for this protein in the development of 
the heart 33. However, absence of TN-X in gene targeted mice did not result in 
an apparent cardiac phenotype, but resulted in reduction of collagen content in 
the skin with loss of tissue strength 3. In addition, absence of TN-X resulted in 
increased activities of MMP-2 and MMP-9 17. Whether TN-X may regulate MMP 
activity, thereby affecting rupture or dilatation, or influence cardiac healing and 
remodeling after cardiac injury, requires further investigation. 
3. Osteonectin
Osteonectin (also known as: Secreted Protein Acidic and Rich in Cysteine; SPARC 
or BM-40) is a 32-kDa glycoprotein that belongs to the family of matricellular 
proteins 34. Expression of osteonectin is high during embryonic development, but 
very low during normal postnatal life, except in tissues undergoing continuous 
remodeling, such as the gut and bone 35, 36. However, osteonectin expression 
reappeared after pathological insults, like myocardial infarction 37, 38, and in 
malignant tumours 39, indicating a role in cell migration and matrix remodeling 
during pathological conditions.  
Its implication in remodeling may occur through binding to TSP1, vitronectin, 
entactin, fibrillar collagens and collagen type IV 40, thereby regulating matrix orga-
nization. In addition, osteonectin is a substrate for transglutaminase, an enzyme 
that makes covalent cross-links between matrix proteins 41, mediating matrix 
assembly and cell-ECM interactions. Osteonectin expression also correlated with 
progression of different tumours 42-45. Increase in MMP-2 activity by osteonectin, 
as shown in invasive human breast 46 and prostate cell lines 47, may in part explain 
increased invasiveness associated with increased expression of osteonectin. 
Matricellular proteins in the heart
20
Another important property of osteonectin is its counteradhesive activity. Addition 
of osteonectin to cultured endothelial cells caused dissociation of focal adhesion 
of endothelial cells to the matrix, resulting in modified cell shape with rounding 
of endothelial cells 48. However, the exact mechanism of de-adhesion induced by 
osteonectin is incompletely understood 48. 
Use of osteonectin deficient mice provided new insights in the function of 
osteonectin regarding cell function and matrix remodeling during wound 
healing, as already suggested by increased expression of osteonectin after injury. 
Indeed, osteonectin-null mice showed an altered cutaneous wound healing 5, 6. 
Together, these data indicate a crucial role of osteonectin in matrix assembly and 
reorganization, and in cell-matrix interaction during tissue injury and remodelling. 
3.1 Osteonectin in the heart
Expression of osteonectin is abundant in the heart during fetal development 35, 36. 
In contrast, its expression in the heart is almost absent during adulthood 36, but re-
appears in the heart after myocardial infarction 37, 38 or adrenergic stimulation 49. 
Absence of osteonectin in mice during embryogenesis resulted in smaller collagen 
fibrils that were more uniform in diameter 50, with curly tails and reduced tensile 
strength of the skin. 
Whether absence of osteonectin may also alter formation of collagen in the 
normal heart is unknown. Expression of osteonectin mRNA strongly increased 
after myocardial infarction in the infarct zone of the rat heart, reaching a peak 
after 14 days 37, 38. Its expression paralleled the up-regulation of type I collagen 
mRNA after myocardial infarction, suggesting an implication of osteonectin in 
development of fibrosis during scar formation 37. Osteonectin mRNA was also 
up-regulated in cardiac remodeling 3 and 7 days after ß-adrenergic stimulation 
49. Osteonectin may modulate matrix remodeling and wound healing in the 
heart by different ways. First, osteonectin may alter activity of growth factors, 
including TGF-ß, bFGF, PDGF and VEGF, which are involved in wound healing after 
cardiac injury 40, 51, 52. Secondly, osteonectin may induce de-adhesion, involved in 
stimulating invasion of wound healing cells, but also facilitating myocyte slippage 
and cardiac dilatation. Finally, osteonectin may modulate angiogenesis 53-55, and 
might thereby influence infarct healing and function after myocardial injury. 
Whether osteonectin up-regulation after cardiac injury or during hemodynamic 
stress may be beneficial or detrimental for cardiac structure or function requires 
further investigation.
Chapter 2
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4. Osteopontin
The matricellular protein osteopontin (OPN) is to date the most extensively studied 
one regarding its role in the myocardium. OPN is highly expressed during embryonic 
development 56, 57. However, OPN expression is low in normal postnatal life except 
for the kidney, bone, and in epithelial linings of several tissues 58. As described for 
other matricellular proteins, OPN expression clearly increased during pathological 
conditions, such as cancer 59, atherosclerosis 60, myocardial infarction 61, and focal 
stroke 62, indicating a role of OPN in matrix remodeling and cell-matrix interaction 
in diseased tissue. OPN is a multifunctional protein, not only expressed by bone 
cells, but also by inflammatory and wound healing cells, including macrophages, 
endothelial cells, smooth muscle cells and fibroblasts 63. It mediates wound 
healing by regulating cell adhesion, migration and proliferation 7. OPN has both 
pro- and anti-inflammatory effects 64 by regulating inflammatory cell adhesion 
65, 66, migration 65, 66, cytokine release 67, 68, and differentiation state 69. As a pro-
inflammatory agent, it appears to be crucial for the recruitment of macrophages 
to inflamed sites 66, 70. Inflammatory effects of OPN were clearly shown in mice 
lacking OPN. Lack of OPN also resulted in impaired wound healing after skin 
incisions with abnormal collagen formation and pronounced disorganization of 
the matrix 71. In conclusion, OPN appears to be a key player in matrix remodelling 
and wound healing. 
4.1 Osteopontin in the heart
Based on current literature, expression of OPN has never been demonstrated in the 
developing heart. OPN is expressed in cultured neonatal myocytes of rats, but its 
expression is absent in normal human myocardium 72.  OPN expression reappears 
in response to injury. Indeed, increase of OPN was described after myocardial 
infarction, primarily in non-muscle cells in the interstitial space –probably 
infiltrating inflammatory cells- 37, 61, 73, reaching its peak 2 to 3 days after the 
infarction. OPN also colocalized with interstitial fibroblasts in hypertrophic hearts 
of spontaneous hypertensive rats 74, rat hearts undergoing thermal injury 75, and 
in hypertrophic hearts of cardiomyopathic hamsters 76. OPN expression coincided 
with the development of heart failure, and in situ hybridization revealed primarly 
interstitial cells, probably fibroblasts, as the major source of OPN. In human 
hearts however, OPN expression was primarly present in myocytes of explanted 
hearts with ischemic, hypertrophic or idiopathic dilated cardiomyopathy . In situ 
hybridization indeed revealed cardiomyocytes as the dominant source of OPN 
synthesis and expression did not correlate with inflammatory cell invasion 72.  Clear 
genetic evidence for a crucial role of OPN in cardiac healing and remodeling was 
provided in OPN-null mice. Absence of OPN resulted in exaggerated LV dilatation, 
and decreased collagen deposition in both the infarcted and remote area of 
Matricellular proteins in the heart
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the heart after myocardial infarction 61. Up-regulation of OPN after myocardial 
infarction thus protected against LV dilatation, implying a beneficial role for OPN in 
LV remodeling when coping with cardiac stress. Whether OPN-mediated decrease 
in MMP activity 77 may also be implicated in LV remodeling after myocardial injury 
has not been investigated. Taken together, OPN upregulation may be necessary to 
maintain cardiac structure and function during cardiac injury or stress.
5. Thrombospondin 1 & 2
Thrombospondin (TSP) 1 and 2 belong to the thrombospondin family of 
extracellular glycoproteins, consisting of TSPs 1-5. TSP1 and TSP2 expression is 
high during embryogenesis, but spatial and temporal expression of TSP1 during 
embryogenesis differs from TSP2 78-80.  During normal postnatal life, the expression 
of TSP1 and TSP2 is low. TSPs exert their function at the cell surface, where they 
bind to membrane proteins and cytokines, thereby regulating ECM structure and 
cellular phenotype. The three main molecular functions of TSP1 are activation of 
TGF-ß, inhibition of angiogenesis and de-adhesion. First, TSP1 is a major activator 
of TGF-ß1 in vivo 81. Secondly, TSP1 was the first naturally occurring protein to 
be identified as an angiogenesis inhibitor 82. TSP1 directly inhibits angiogenesis 
by induction of apoptosis and inhibition of migration of endothelial cells 83, and 
may indirectly inhibit angiogenesis by modulation of inflammatory cells and 
myofibroblasts 84. Finally, TSP1 also induces de-adhesion in a variety of cells, 
including fibroblasts and endothelial cells 85, by stimulating the loss of focal 
adhesions and actin stress fibers 85, 86. Despite its array of functions, the TSP1 null 
mice showed only a subtle phenotype, including mild spinal lordosis, acute and 
chronic inflammatory pulmonary infiltrates and an elevated number of white 
blood cells in the circulation 87.  
As described for TSP1, TSP2 also inhibits angiogenesis and causes de-adhesion. 
Gene inactivation of TSP2 in mice indeed increased capillary density in various 
tissues at all stages of life 4. Besides its anti-angiogenic function, TSP2 also inhibits 
focal adhesion in endothelial cells 88, 89. Absence of TSP2 in fibroblasts, however, 
caused defective attachment and spreading on matrix proteins, like fibronectin 
4, 90. Increased levels of MMP2 activity in absence of TSP2 may in part explain 
the defect in fibroblast adhesion. The TSP2 null mice showed a more dramatic 
phenotype, as compared to TSP1 null mice, including a fragile skin associated with 
an abnormal collagen fibrillogenesis, increased vascularity in response to injury, 
increased cortical bone density, and a bleeding diathesis 4, 79. In conclusion, TSP1 
and TSP2 are involved in wound healing by regulating growth factor signaling, 
angiogenesis and cellular adhesion.
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5.1 Thrombospondin 1 and 2 in the heart
Both TSP1 and TSP2 are expressed in the heart during development, whereas their 
expression is low during normal postnatal life. However, TSP1 and TSP2 expression 
reappears in response to injury, implicating that, if the same occurs in the heart, 
these proteins could be involved in the LV remodeling during/after pathological 
events in the heart, such as myocardial infarction, or chronic pressure overload. 
TSP1 null mice may show an interesting phenotype after pathological insults in the 
heart. It is known that TSP1 null mice have a delayed wound healing associated 
with a reduced inflammatory response 87. A delayed healing after, for instance, 
myocardial infarction may result in a reduced LV function. 
TSP2 null mice display an abnormal collagen fibrillogenesis after birth and 
during cutaneous wound healing 9, 87. An important issue is whether collagen 
formation may be abnormal after cardiac injury or stress, resulting in abnormal 
cardiac remodeling and impaired cardiac function.  Preliminary results indeed 
demonstrated that myocardial infarction in TSP2 null mice resulted in cardiac 
rupture 48 hours after myocardial infarction in more than 90% of the null mice 91. 
This striking phenotype suggests that TSP2 is essential to LV remodeling after 
myocardial infarction, and may have an important role to maintain matrix 
integrity in the heart. Preliminary, yet unpublished data indicate that altered 
collagen formation may in part explain increased cardiac rupture after myocardial 
infarction. Whether increased inflammation in absence of TSP2 may predispose 
to weakening of the matrix, however, remains a vital question. Together, TSP2 
appears to play a pivotal role in maintenance of cardiac integrity and structure. 
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6. Are matricellular proteins essential for the heart to cope 
with hemodynamic stress?
The matricellular proteins are a group of ECM binding proteins that exert their 
function by binding to matrix proteins, cell surface receptors or molecules such as 
cytokines. They do not have a direct structural role in the matrix, but modulate cell 
function and cell-matrix interactions 1. Most of the matricellular proteins show an 
increased expression in the heart in response to injury or stress, which suggests 
a vital function of these proteins in wound healing and ventricular remodeling 
12, 37, 61. These matricellular proteins may alter cardiac remodeling by different 
ways. First, they may initiate de-adhesion between cardiomyocytes and the ECM, 
meaning the transformation from a strong cell-ECM adhesion to an intermediate 
cell-ECM adhesion, which allows cells to spread (figure 1) 2. Secondly, matricellular 
proteins can decrease 17, 77, 92, or increase 26, 46, 47, 93 (figure 1, table 1) proteinases 
involved in cardiac remodeling and function in different cardiac diseases 27, 94. 
Gene inactivation in mice in combination with cardiac disease models provides 
a unique tool to study the role of each individual matricellular protein in the 
stressed or injured heart. The null mice of the matricellular proteins all survived 
during embryogenesis, and only showed a mild phenotype. However, most of 
the null mice showed an altered response to wound healing, with changes in 
inflammation, angiogenesis, collagen fibrillogenesis or matrix deposition (table 1).
Strong adhesion
(focal adhesion, stress fibers)
TN-C, TSP1, TSP2, Osteonectin, OPN
Intermediate adhesion
(cell migration)
Figure 1. A hypothetical scheme showing the possible role of the matricellular proteins in during LV remodeling of the 
heart. Expression of matricellular proteins increases in response to stress. Matricellular proteins induce de-adhesion 
(loosening of cell-matrix adherence), through loss of actin fibers and focal adhesion plaques. Thereby, matricellular 
proteins facilitate cell migration and cell infiltration. Matricellular proteins also regulate MMP activity, involved in 
regulating matrix rearrangement during remodeling of the heart.
STRESS
OPN
TN-X
TSP-2
TN-C
TSP-1
Osteonectin
Fibroblast
Macrophage
  myocyte      myocyte 
MMPs
Focal adhesion
Membrane receptor
Actin stress fiber
Dynamic tissue
(remodeling)Static tissue
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Table 1: MMP activity regulation by matricellular proteins and characteristics of matricellular protein null mice.
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Recently, the role of OPN and TSP2 after myocardial infarction has been examined 
in their respective null mice. Both the OPN and the TSP2 null mice showed a clear 
phenotype after MI. The OPN null mice had an exaggerated left ventricle dilatation 
61, whereas > 90% of the TSP2 null mice died after myocardial infarction due to 
cardiac rupture 91. These data are striking and show that both OPN and TSP2 are 
necessary to maintain a normal cardiac structure and function after myocardial 
injury. 
The multiple parallel features of the matricellular proteins suggest that, besides 
OPN and TSP2, also other family members may have crucial functions during 
ventricular remodeling of the stressed heart. More research is needed to clarify 
the roles of these matricellular proteins during ventricular remodeling in the 
injured heart.
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Abstract
Background The matricellular protein SPARC (secreted protein acidic and rich in 
cysteine, also known as osteonectin) mediates cell-matrix interactions during 
wound healing and tumorigenesis. The current study investigated whether 
SPARC also regulates cardiac remodeling and matrix maturation after myocardial 
infarction (MI).
Methods and Results. SPARC protein expression after MI increased from 3 days 
on, reaching its maximum at day 14. Targeted deletion of SPARC in mice resulted 
in increased mortality compared with wild type (WT) mice after MI. About 41 % 
of the SPARC knockout mice (13/32) succumbed within 5 days after MI due to 
cardiac rupture, in contrast to 8.8 % rupture (3/34) in WT. The absence of SPARC 
resulted in the formation of a disorganized granulation tissue and dismature 
collagen matrix in the infarcted area, leading to increased cardiac dysfunction 
after hemodynamic stress. This crucial involvement of SPARC in infarct healing is 
in part due to its regulatory role in transforming growth factor-ß (TGFß) signaling. 
In vitro, lentiviral mediated knockdown of SPARC by short hairpin RNA attenuated 
phosphorylation of SMAD2 after TGFß stimulation, whereas infusion of TGFß in 
SPARC KO mice rescued cardiac rupture and infarct healing.  
In conclusion, SPARC is essential for normal infarct healing and cardiac integrity 
after MI, partly via regulation of TGFß signaling. 
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Introduction
Secreted Protein, Acidic and Rich in Cysteine (SPARC, also called osteonectin or 
BM-40) belongs to the family of matricellular proteins, which are non-structural 
proteins in the matrix capable of modulating cellular responses. As for other 
matricellular proteins, SPARC is involved in tumor formation and wound healing 
by modulating cell-matrix interaction 1,2. However, evidence on a specific role for 
SPARC in formation of granulation and scar tissue after myocardial infarction (MI) 
is lacking. 
Healing after MI requires a tightly regulated process of wound healing and scar 
formation. Alteration in this well-orchestrated response to myocardial necrosis 
leads to adverse infarct healing, cardiac rupture and dysfunction 3. Expression of 
SPARC is increased after MI, and is spatially and temporally related to the formation 
of a fibrous scar 4,5. SPARC may modulate extracellular matrix turnover through its 
effect on collagen, extracellular proteases and growth factors 1. 
Transforming growth factor –ß (TGFß) is a cytokine involved in wound healing 
and collagen production, and has an important role in LV remodeling after MI. 
SPARC is able to modulate TGFß signaling by binding to the TGFß receptor type 
II, and the absence of SPARC resulted in decreased SMAD phosphorylation 6,7. 
We hypothesized that its local expression after MI acts as a modulator of scar 
maturation, partly through TGFß signaling, and thereby protects against cardiac 
rupture and dysfunction. 
Here, we show that loss of SPARC results in abnormal collagen formation 
and increased cardiac rupture and dysfunction after MI. Increased matrix 
metalloproteinase (MMP) activity and reduced TGFß signaling in the absence of 
SPARC contributed to the formation of an immature scar, as indicated by increased 
MMP-2 and MMP-9 activity in SPARC deficient mice and by shRNA-mediated SPARC 
knockdown in cardiac (myo)fibroblasts. In concordance, exogenous administration 
of TGFß in SPARC deficient mice rescued increased infarct rupture after MI.
In conclusion, increased expression of SPARC after MI is essential for proper infarct 
healing and collagen maturation, thereby protecting against cardiac rupture, 
dilatation and dysfunction.  
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Methods
Mouse model of myocardial infarction
All described study protocols were approved by the Animal care and use 
committee of the Universiteit Maastricht. Experiments were performed according 
to the official rules formulated in the Dutch law on care and use of experimental 
animals. Ten to eighteen weeks old male and female SPARC KO and WT with a 
c57/BL6 x Sv129 background were used in this study. Experimental myocardial 
infarction and sham operation was performed as described previously 8.  Three 
days, one week and two weeks after surgery, cardiac function was assessed before 
euthanasia. Hearts were perfused with phosphate saline buffer, taken out and 
prepared for molecular, histological and ultrastructural analysis.
Histology and Electron Microscopy
Cardiac tissue was processed as described previously 8. Sections were stained 
with hematoxylin/eosin for detection of infarct size and thickness. Next, collagen 
was stained on cardiac sections using Sirius red, and the amount of collagen was 
quantified 8,9. Quality of collagen fibers was investigated by Sirius red polarization 
microscopy, allowing to quantify tightly packed collagen fibers as orange-red, and 
loosely assembled fibers as yellow-green 10.  
Ultrastructural analysis was performed as described previously 9. Immunohis-
tochemistry on paraffin sections was performed using antibodies against CD45 
(leukocytes), SPARC (R&D, Abingdon, UK) and alpha-smooth muscle cell actin 
(SMA, coronary vessels) (Dako, Leuven, Belgium) 8,9. CD45–staining leukocytes, and 
SMA-staining vessels and myofibroblasts were quantified in the area of infarction 
as described previously 8,9. 
Cardiac fibroblast culture & Lentiviral constructs
Cardiac fibroblasts were isolated from 2-day-old neonatal Lewis rats. All the 
experiments were performed on cells from the second passage. Cells were 
maintained in DMEM supplemented with 10% FBS along with 0.1% gentamycin, 
and were incubated at 37°C in a humidified chamber. Small interfering RNA 
(siRNA) against SPARC was designed by Eurogentec, Liège, Belgium.  From this 
design oligo’s with one hairpin loop were created (shRNA, table 5). The oligo’s 
were cloned into XhoI and HpaI site of the vector pLenti Lox 3.7 puro. This vector 
was modified from the pLenti Lox 3.7 11 by replacing the eGFP gene by puromycin. 
Constructs were verified by sequencing. Lentiviral production was performed by 
co-transfection of 3 µg shSPARC/pLL3.7 puro or empty pLL3.7 puro and packaging 
vectors into 293FT cells by Lipofectamine 2000 (Invitrogen) and virus-containing 
supernatant was harvested after 48 hours. SPARC knockdown in cardiac fibroblasts 
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was established by treating cells with lentivirus containing shRNA against SPARC 
for 48 hours. After puromycin selection, cells were placed in low-serum medium 
(0.4% FBS) for 24 hours. Thereafter, cells received TGFß (1ng/ml) for 15 minutes, 
and were harvested for Western blotting.
Sham 7 days 14 days
WT 
n=11
KO
 n=11
WT
 n=8
KO
 n=7
WT
 n=10
KO
 n=11
FS, % 26±1.3 30±1.9 18±3.1† 15±7† 12±1.4† 12±1.2†
LVIDd, mm 3.7±0.1 3.6±0.1 4.7±0.2† 4.9±0.5† 5.0±0.3† 5.3±0.2†
LVIDs, mm 2.8±0.1 2.6±0.1 3.9±0.3† 4.3±0.6† 4.4±0.3† 4.7±0.3†
IVSd, mm 0.9±0.1 1.0±0.1 1.0±0.2 0.9±0.1 0.8±0.1 0.8±0.1
IVSs, mm 1.2±0.1 1.4±0.1 1.4±0.1 1.2±0.2 1.0±0.2 0.9±0.1
HR, bpm 698±18 659±6 699±9 717±16 698±19 644±21
LVW/BW 4.4±0.2 4.2±0.2 5.6±0.2† 6.7±1.2† 5.0±0.2† 5.8±0.2*†
LW/BW 6.6±0.4 6.0±0.2 9.7±1.3† 10.4±1.2† 10.1±1.3† 9.8±1.2†
Western Blotting and MMP Zymography
Western blotting was performed as described previously. Cell lysates were 
applied to SDS-PAGE and immunoblotted for the detection of phosphorylated 
and total SMAD2, as described by others 12. Zymographic activity of matrix 
metalloproteinase (MMP)-2 and –9 in infarcted and sham hearts were performed 
as described previously 8,13.
FS, fractional shortening; LVIDd, left ventricular diameter diastole; LVIDs, left ventricular diameter systole; IVSd, 
intraventricular septum diastole; IVSs, intraventricular septum systole; HR, heart rate; LVW, left ventricular weight; BW, 
body weight and LW, lung weight.
†P<0.05 in infarcted vs. sham
*P<0.05 in SPARC KO vs WT infarcts
Table 1. Functional analysis of SPARC WT and KO mice after MI
SPARC and myocardial infarction
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RNA isolation and expression
RNA was isolated from infarcted and sham tissue using the RNeasy Mini Kit 
(Qiagen) and stored in -80ºC. RNA was reverse transcribed into cDNA using the 
iScript™ cDNA synthesis kit (BioRad). Real-time quantitative PCR was performed 
using iQ™ SYBR green supermix (BioRad) and primers designed with Primer 
Express Software (PE Applied Biosystems, Foster City, CA). Cyclophilin was used as 
a housekeeping gene. Primers used are shown in table 5.
Figure 1. SPARC expression after MI. Immunostaining of SPARC increased from 3 days after MI, while peaking at 14 
days. A: Typical example of SPARC expression 14 days after MI. B: SPARC is produced by (myo)fibroblasts surrounding 
the necrotic cardiomyocytes. C: Quantification of SPARC staining. D: Survival curve of SPARC KO and WT mice after 
myocardial infarction. E: SPARC KO mice display cardiac dysfunction after hemodynamic stress.*P<0.05
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Echocardiography & Functional assessments
Standard views were obtained in 2-D as well as M-mode by transthoracic 
echocardiography with a 12-MHz transducer (Hewlett Packard, Amsterdam, 
The Netherlands) on a Sonos 5500 (Hewlett Packard) echocardiograph. Cardiac 
contractility was measured using a 2F Millar microtip catheter (Millar instruments) 
as described before 14.
TGFß infusion 
To investigate whether exogenous administration of TGFß may rescue increased 
cardiac rupture after MI, SPARC KO mice were treated with TGFß (250 ng/day) 
versus saline using osmotic minipumps for 7 days, starting 1 day before the 
induction of MI. 
Statistical analysis
Data were expressed as mean ± SEM.  No repeated measures were performed. 
Echocardiographic measurements and histological and molecular analysis in 
sham-operated and infarcted groups at 3, 7 and 14 days were all performed in 
independent groups. Normal distribution of all continuous variables was tested 
using the method of Kolmogorov and Smirnov. An unpaired t-test was used in most 
of the comparisons when groups passed the normality test. However, a Mann-
Whitney test was used when the standard deviations of two groups significantly 
differed. A two sided P value < 0.05 was considered statistically significant.
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Table 2. Histological analysis and determination of collagen in infarcted area.
SPARC WT, 
MI, 3 days 
n=11
SPARC KO, 
MI, 3 days, 
n=11
SPARC WT, 
MI, 7 days 
n=8
SPARC KO, 
MI, 7 days 
n=7
SPARC WT,  
MI, 14 days 
n=10
SPARC KO 
MI, 14 days 
n=11
Infarct size, % 49±2.3 44±3.3 43±3.6 46±4.1 42±2.6 43±2.7
Residual necrotic 
area, %
N.D. N.D. 9.6±1.8 9.6±2.2 2.7±0.7 1.0±0.3*
Infarct thickness, 
µm
384±25 390±38 377±61 291±22 390±27 379±27
Leukocyte 
infiltration, cells/
mm2
964±186 1097±101 874±182 821±143 659±131 272±68*
Coronary growth, 
vessels/ mm2
N.D. N.D. 42.1±3.7 44.9±4.8 53.6±9.7 42.8±4.8
Myofibroblast, % 
area
N.D. N.D. 2.1±0.37 3.8±0.84* 0.76±0.37 1.61±0.16*
Collagen 
depostion, %
N.D. N.D. 26±2.5 20±3.6 36±2.4 37±2.0
Ratio O-R thick/Y-G 
thin collagen fibers 
N.D. N.D. 11±2.3 2.5±0.5* 17.2±1.8 8.1±1.8*
Results
 
Increased SPARC protects against cardiac rupture and dysfunction 
Immunostaining revealed increased expression of SPARC at 3 days after MI, 
progressively increasing 7 and 14 days after MI (figure 1C), concordant with previous 
findings 4,5. SPARC immunostaining was mainly located in (myo)fibroblasts, 
surrounding the necrotic cardiomyocytes (Figure 1A,B). Absence of SPARC resulted 
in a significantly increased cardiac rupture after myocardial infarction: 41% 
(13/32) of SPARC KO mice (males: 8/12; females: 5/20) compared to 8.8% (3/34) 
of WT mice (males: 2/14; females: 1/20) died due to cardiac rupture (Figure 1D). 
Male SPARC KO mice that survived cardiac rupture displayed severe shortness of 
breath within 7 days and died prematurely. Left ventricular pressure (LVP) and 
heart rate were similar in sham operated and infarcted WT and SPARC KO mice 
in baseline conditions. Contractility (dP/dtmax corrected for systolic pressure) was 
reduced in infarcted compared with sham-operated mice at 14 days, but to a 
similar extent in both genotypes. Hemodynamic stress induced by dobutamine 
increased contractility in WT mice after MI, but significantly less in SPARC KO mice 
(Figure 1E). 
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Disorganized granulation tissue and impaired collagen quality in SPARC KO animals 
after MI
Infarct size did not differ between SPARC WT and KO mice (Table 2). Histological 
analysis of infarcts revealed a disorganized granulation tissue with increased red 
blood cell infiltration in SPARC deficient infarcts (figure 2). Adverse infarct healing 
in SPARC KO mice was not related to significant differences in inflammation or 
vascular density compared to WT mice, but to formation of an immature matrix 
in the absence of SPARC. Sirius red-polarization microscopy of collagen fibers 
revealed a predomination of loosely assembled –yellow green- collagen fibers 
in SPARC KO infarcts at 14 days (ratio of orange-red/yellow-green birefringent 
collagen), in contrast to the well-aligned and thick tightly packed –orange red- 
fibers in WT infarcts. Ultrastructural analysis confirmed a disorganized and 
fragmented collagen matrix in SPARC KO infarcts, in contrast to the well-organized 
collagen matrix in WT infarcts (Figure 3). Absence of SPARC did not affect collagen 
synthesis, as indicated by similar transcript levels of collagen type I and III and 
amount of collagen SPARC KO compared with WT infarcts (Table 3, Figure 3). Thus, 
increased cardiac rupture and dysfunction in SPARC KO mice is caused by deficient 
maturation of the collagen matrix after MI.
SPARC WT, 
n=4-6
SPARC KO, 
n=4-6
Sham
Collagen I
Collagen III
Fibronectin
MI, 7 days
Collagen I
Collagen III
Fibronectin
MI, 14 days
Collagen I
Collagen III
Fibronectin
0.12 ± 0.01
  0.05 ± 0.007
0.05 ± 0.01
1.18 ± 0.23†
0.91 ± 0.16†
0.81 ± 0.14†
2.03 ± 0.36†
1.50 ± 0.26†
1.58 ± 0.32†
0.10 ± 0.01
  0.07 ± 0.007
0.08 ± 0.01
1.14 ± 0.08†
0.97 ± 0.08†
0.87 ± 0.13†
1.79 ± 0.23†
1.49 ± 0.14†
1.81 ± 0.32†
SPARC and myocardial infarction
†P<0.05 in infarcted vs. sham
Table 3. Transcript levels of extracellular matrix genes after MI.
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SPARC modulates MMP-activity.
Since SPARC mediates wound healing and matrix maturation by interaction with 
growth factors and matrix proteins 1,2, activity of MMP-2 and -9 was investigated. 
MMP zymography revealed significantly increased activity of MMP-2- and MMP-9, 
both involved in cardiac rupture 8,15, in SPARC KO compared with WT infarcts at 3 
days (Figure 4C and 4D).  
 
Table 4. Histological analysis and determination of collagen in infarcted area.
SPARC WT,  7 
days, n=8
SPARC KO,  7 
days, n=9
SPARC KO + TGF ß, 
7 days, n=6
Infarct size, % 42.7±3.6 45.9±4.1 36±4
Residual necrotic area, % 9.6±1.8 9.6±2.2 3.9±1.7
Infarct thickness, µm 376.7±61 321.5±26 558.3±71.7*
Collagen depostion, % 25.93±2.5 20.04±3.6 30.3±2.0*
Ratio O-R thick/Y-G thin 
collagen fibers 
11±2.3 2.5±0.5† 4.5±1.2*
LVW/BW 5.6±0.2 6.6±1.0 6.3±0.6
LW/BW 9.7±1.3 10.9±1.4 9.8±0.6
O-R indicates orange-red; Y-G, yellow green; LVW, left ventricular weight; BW, body weight and LW, lung weight.
*P<0.05 in TGFß treated vs. control
†P<0.05 in SPARC KO vs WT infarcts
SPARC modulates TGFß signaling in cardiac fibroblasts
To evaluate the role of SPARC in activating TGFß signaling, we examined SMAD2 
phosphorylation in fibroblasts in vitro, with downregulation of SPARC by adding 
short hairpin (sh)-RNA against SPARC. This resulted in a significant 80% decrease 
in protein expression of SPARC compared with control. TGFß treatment (1ng/ml) 
resulted in a significant increase of phosphorylated SMAD2/SMAD2 ratio in wild 
type fibroblasts, but significantly less after SPARC downregulation (Figure 4A and 
4B). These data indicate a crucial role for SPARC in regulating TGFß signaling in 
cardiac fibroblasts.  
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Figure 2. Adverse wound healing in SPARC KO mice. A, B: Hematoxylin and eosin staining revealed disorganized infarct 
healing in SPARC KO (B) vs. WT (A) infarcts. C, D: Increased red blood cell infiltration in SPARC KO infarcts (D) as compared 
to WT infarcts (C).
SPARC and myocardial infarction
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Figure 3. Abnormal collagen formation in SPARC KO infarcts. A, B: Sirius red analysis revealed no differences in collagen 
deposition between WT (A) and KO (B) infarcts at 14 days. C,D: Sirius red polarization microscopy revealed mainly well-
aligned and tightly packed (orange-red) collagen fibers in WT infarcts (C), but loosely assembled fibers (yellow-green) 
predominating in SPARC KO infarcts (D). E, F: Ultrastructural analysis confirmed a disorganized matrix in SPARC KO (F) 
vs WT (E) infarcts.
Infusion of TGFß protects against cardiac rupture in SPARC KO mice
TGFß is strongly implicated in infarct healing and remodeling after MI. To investigate 
whether aberrant TGFß signaling in absence of SPARC may be involved in adverse 
infarct healing and increased cardiac rupture after MI, SPARC KO mice were 
treated with TGFß. TGFß-treatment in SPARC KO significantly improved survival by 
decreasing cardiac rupture (cardiac rupture: 1 out of 7 in TGFß- compared with 8 
out of 12 in saline-treated SPARC KO mice) (Figure 6). Histological analysis revealed 
increased deposition of collagen in TGFß- compared with saline-treated SPARC KO 
mice (Table 4, Figure 5).
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Discussion
The present study unveils a crucial role for SPARC in regulating infarct healing 
and collagen maturation after myocardial infarction.  Absence of SPARC resulted 
in adverse infarct healing, deficient maturation of collagen and decreased TGFß 
signaling, leading to increased cardiac rupture and dysfunction.  Treatment with 
TGFß prevented cardiac rupture in SPARC KO infarcted mice, underscoring an 
important role for SPARC -mediated TGFß signaling in infarct healing. 
Table 5. Primers and shRNA sequence
Gene Fw primer 5’ –  3’ Rev primer 5’ –  3’
Collagen I CTTCACCTACAGCACCCTTGTG CTTGGTGGTTTTGTATTCGATGAC
Collagen III TCGGAACTGCAGAGACCTAAA CCCCAGTTTCCATGTTACAGA
Fibronectin ATGTGGACCCCTCCTGATAGT GCCCAGTGATTTCAGCAAAGG
Cyclophilin CAAATGCTGGACCAAACACAA GCCATCCAGCCATTCAGTCT
ShRNA SPARC sequence
Sense 5’- 3’ ggtggaaatgggagagtttttcaagagaaaactctcccatttccacctttttc
Antisense 5’- 3’ tcgagaaaaaggtggaaatgggagagttttctcttgaaaaactctcccatttccacc
Figure 4. ShRNA against 
SPARC inhibits SMAD2 
phosphorylation. A: 
Lentiviral mediated 
shRNA against SPARC 
strongly decreases SPARC 
expression in neonatal 
cardiac fibroblasts. B. 
SMAD2 phosphorylation in 
shRNA knockdown cardiac 
fibroblasts is significantly 
decreased after 15 minutes 
of TGFß stimulation (1 
ng/ml). C,D. Significantly 
increased zymographic 
activity of MMP-2 (C) and 
MMP-9 (D) in SPARC KO 
infarcts vs WT infarcts at 3 
days after MI.
SPARC and myocardial infarction
48
Expression of SPARC progressively increases after MI in rats and dogs 4,5 and is 
mainly expressed by fibroblasts, suggesting a role for SPARC in maturation of 
the infarct scar.  Here, gene inactivation of SPARC resulted in increased cardiac 
rupture and dysfunction, due to a disorganized and fragmented granulation, and 
abnormal collagen maturation. These findings are consistent with a role for SPARC 
in cutaneous wound healing 16, cataract formation and -foreign body reaction.17
Figure 5. TGFß infusion in SPARC KO mice protects against cardiac rupture after MI, due to increased ECM deposition. 
A-D: Hematoxylin and eosin staining reveals striking differences between SPARC WT and KO mice 7 days after MI. E, F: In 
SPARC KO mice TGFß infusion accelerates infarct healing and stimulates ECM production to strengthen the infarct zone. 
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In the present study, amount of collagen did not differ between SPARC KO and 
WT infarcts, but ultrastructural analysis revealed a disorganized and immature 
collagen matrix. SPARC may regulate infarct healing and collagen maturation 
by different ways. First, SPARC directly interacts with collagen type I fibers18 and 
thereby regulates their assembly.  Variation in the structure of SPARC will directly 
alter its affinity to collagen type I. Lack of SPARC also results in formation of 
immature collagen fibers during wound healing in the skin16 and in response to a 
foreign body17. 
Secondly, SPARC regulates TGFß signaling in cardiac fibroblasts, as revealed 
by our in vitro experiments showing reduced TGFß-Smad2 signaling by SPARC 
downregulation. These findings are concordant with previous observation in 
epithelial19 and mesangial6 cells. The latter study showed that SPARC directly 
binds to the TGFß receptor type II, and that, consequently, SPARC null mesengial 
cells displayed less SMAD2 phosphorylation.  Another study revealed that siRNA-
mediated down-regulation of SPARC attenuates SMAD3 phosphorylation and 
collagen production in skin fibroblasts.7 TGFß is a cytokine involved in wound 
healing and collagen production, and has an important role in LV remodeling after 
MI 20:  inhibition of TGFß in the first day after MI has detrimental effects on cardiac 
performance 21. Our findings that treatment with TGFß prevented infarct rupture in 
SPARC KO mice provide strong in vivo evidence on a crucial role of SPARC-mediated 
TGFß signaling in infarct healing.  Finally, absence of SPARC resulted in increased 
activity of MMP-2 and -9, both facilitating fatal cardiac rupture 8,22,23. SPARC is able 
to induce activation of both MMP-2 and MMP-9 (reviewed in24). In turn, MMP-2 
proteolytically cleaves SPARC, which increases the affinity of SPARC for collagen 
and thereby promotes maturation of collagen by SPARC. Their increase did not 
result from a difference in inflammatory response in SPARC KO infarcts, but may 
evolve from increased presence of myofibroblasts that produce both MMPs25.
Figure 6. Survival curve showing that TGFß 
infusion protected against cardiac rupture in 
SPARC KO mice.
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SPARC KO animals showed increased accumulation of myofibroblasts. A paradoxal 
increase in myofibroblasts density despite decreased TGFß signaling was also 
reported in mice lacking thrombospondin-1, another matricellular protein 
modulating TGFß signaling 26. Increased myofibroblast presence may have resulted 
from increased migration of myofibroblasts in the absence of SPARC 27, resulting 
in an impaired scar maturation.  
Lately, evidence on a central role of matricellular proteins in cardiac wound 
healing and remodeling is increasingly appreciated. These proteins, which are 
hardly expressed in the normal, intact heart, are highly upregulated in the injured 
heart. Recent publications revealed the importance of other matricellular proteins 
including thrombospondin-126, osteopontin28, tenascin-C29 and syndecan-130 in 
wound healing of the infarcted heart 26,28. Thrombospondin-1 and syndecan-1 are 
expressed early after MI and serve as a “barrier” limiting influx of inflammatory 
cells, thereby regulating proper infarct healing and preventing infarct expansion 
and cardiac dilatation. In contrast, osteopontin, tenascin-C and SPARC are mainly 
expressed during the formation of granulation tissue and fibrous scar, and are 
implicated in arrangement and maturation of collagen fibers.
Taken together, SPARC expression after MI is essential for the proper healing of the 
infarct, by mediating TGFß signaling and regulating collagen matrix maturation. 
These results emphasize a crucial role for matricellular proteins during infarct 
healing, indicating that these proteins are well-fit candidates for therapeutic 
interventions to prevent heart failure after myocardial infarction. 
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Abstract
Background. The cell-associated proteoglycan Syndecan-1 (Synd1) closely regulates 
inflammation and cell-matrix interactions during wound healing and tumori-
genesis. The current study investigated whether Synd1 may also regulate cardiac 
inflammation, matrix remodeling, and function after myocardial infarction (MI).
Methods and Results. First, we showed increased protein and mRNA expression of 
Synd1 from 24 hours on, reaching its maximum at 7 days after MI and declining 
thereafter. Targeted deletion of Synd1 resulted in increased inflammation and 
accelerated, yet functionally adverse, infarct healing after MI. In concordance, 
adenoviral gene expression of Synd1 protected against exaggerated inflammation 
after MI, mainly by reducing transendothelial adhesion and migration of 
leukocytes, as shown in vitro. Increased inflammation in the absence of Synd1 
resulted in increased monocyte chemoattractant protein-1 expression, increased 
activity of matrix metalloproteinase-2 and –9, and decreased activity of tissue 
transglutaminase, associated with increased collagen fragmentation and 
disorganisation. Exaggerated inflammation and adverse matrix remodeling in 
the absence of Synd1 increased cardiac dilatation and impaired systolic function, 
whereas gene overexpression of Synd1 reduced inflammation and protected 
against cardiac dilatation and failure.
Conclusions. Increased expression of Synd1 in the infarct protects against 
exaggerated inflammation and adverse infarct healing, thereby reducing cardiac 
dilatation and dysfunction after MI in mice.
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Introduction
Syndecan-1 (Synd1) is a member of a conserved family of 4 heparan and 
chondroitin sulfate-carrying transmembrane proteins (Synd1, 2, 3, and 4). Synd1 
is emerging as a central regulator of inflammation and matrix remodeling during 
wound healing1,2, infection3, and tumour formation4 (reviewed elsewhere5-7). 
Well-orchestrated interactions between inflammation, extracellular matrix 
components, and cytokines are essential for normal cardiac healing and functional 
recovery after myocardial infarction (MI). However, clear evidence on a specific 
role for Synd1 after MI is lacking. 
Expression of Synd1 is low in normal cardiac tissue, but its expression reappears 
at high levels after MI in rats8,9 and mice10. Considering an essential role of Synd1 
for proper wound healing5-7, we hypothesized that increased expression of Synd1 
after MI may regulate inflammation and normal infarct healing after MI. We 
postulated that absence of Synd1 would increase inflammation, which in turn 
results in increased activity of matrix metalloproteinases (MMPs). Increased MMP 
activity favors degradation of collagens11 and decreases cross-linking of collagens 
by inactivation of tissue-transglutaminase (tTG),12 both resulting in increased 
cardiac dilatation13-16. To address these issues, we investigated infarct healing and 
cardiac function in Synd1-gene-inactivated mice and after adenoviral Synd1-gene 
overexpression. 
Our data reveal that loss of Synd1 resulted in exaggerated inflammation, collagen 
disorganization, and increased cardiac dilatation and failure after MI. In line 
with these findings, overexpression of Synd1 protected against adverse infarct 
remodeling and cardiac failure after MI, indicating a potential therapeutic benefit 
of increased Synd1. 
Methodology
Transgenic mice and model of MI
The present study was approved by our Institutional Animal Research Committee, 
and all experiments were performed according to the official rules formulated in 
the Dutch and German laws on care and use of experimental animals.  We used 
10- to 14-week-old male and female inbred BALB/c Synd1 knockout (KO) (back-
crossed for 11 generations) and their wild type (WT) littermates weighing 20-30 
g. Synd1 mice were a gift from M.A. Stepp, PhD, Washington, DC. MI was induced 
by permanent ligation of the left coronary artery17.  Sham-operation included all 
procedures except permanent ligation.  Hearts were taken out at indicated time 
points and prepared for molecular, histological, and ultrastructural analysis17,18 . 
58
Perioperative mortality rates (24 hours) were 23% and 25% in WT and Synd1 KO 
mice, respectively (P=NS).
Histology and electron microscopy of infarcts
After the study period, infarcted or sham-operated mice were anesthetized, and 
hearts were removed and prepared for further histological and molecular analyses. 
Lungs and the left and right ventricles were dissected, blotted dry, and weighted18 . 
Immunostaining on paraffin sections was performed using antibodies against CD31 
(capillaries), CD45 (leukocytes),  α-smooth muscle cell actin (coronary vessels) (Dako, 
Leuven, Belgium), ε-lysyl γ-glutaminyl cross-links (Abcam, Cambridge, Mass) and 
Synd1 (CD138; Pharmingen, Erembodegem, Belgium) as previously described17,18. 
CD31-staining capillaries, CD45-staining leukocytes, and smooth muscle actin-
staining vessels and myofibroblasts were counted and quantified in the different 
areas through the infarcted left ventricle as described17,18. Morphometric 
analysis was performed with a Leitz DMRXE microscope (Leica Imaging Systems 
Ltd, Solms, Germany), a 3CCD color video camera (DXC-93OP, Sony, New York, 
NY), and a Leica Qwin software system by persons unaware of the genotype.
Syndecan expression
First, in situ hybridization of Synd1 mRNA was performed on cardiac sections at 
1, 4, 7, and 14 days after MI (online Data Supplement, Section I). Synd1 mRNA-
staining cells were counted per square millimeter. Next, Synd1 dot-blot analysis 
was performed in cardiac extracts with determination of total and shed protein 
of Synd12. Finally, to investigate whether absence of Synd1 may result in a 
compensatory increase of other syndecans, mRNA levels of Synd1, 2, 3, and 4 were 
determined by real-time polymerase chain reaction using iQ SYBR green supermix 
(BioRad Laboratories, Hercules, Calif) in infarcts and sham heart at 7 days after MI 
(Online Data Supplement, Section II). 
In vitro leukocyte adhesion and transmigration assays
To obtain polymorphonuclear cells (PMNs), bone marrow was flushed out of the 
hindlimbs of Synd1 KO and WT mice with PBS/1% fetal calf serum, and PMNs were 
purified on Histopaque 1077/1119 gradients (Sigma, Deisenhofen, Germany). 
Purity of the preparation was controlled by flow cytometry or cytospin19. 
Static assays measuring the adhesion of PMNs to the murine bEnd.3 endothelial 
cell line were performed essentially as described19. In short, PMNs were 
fluorescently labeled with 2’7’-bis-(2 carboxyethyl)-5-carboxyfluorescein ace-
toxymethyl ester (Molecular Probes, Eugene, Ore), washed, and incubated in 
triplicates to sextuplets (2 x 106 cells/ml, 50 µl/well) with confluent bEnd.3 
monolayers in 96-well plates (10 min, 37°C). After washing with PBS, adhering 
Chapter 4
 59Syndecan-1 and myocardial infarction
cells were lysed19. The fluorescence signal was quantified in a Spectramax (MTX 
Lab Systems, Inc, Vienna, Va) fluorimeter (excitation 485nm, emission 535nm). 
For transendothelial migration assays, 5 x 105 PMNs in RPMI 1640 medium 
containing 0.5% BSA were added in triplicate to bEnd.3 cells grown for 2 days in 
laminin-coated 6.5 mm Transwells (5-µm pore size, Costar, Bodenheim, Germany). 
The lower chambers contained Dulbecco’s modified Eagle’s medium/10% Fetal 
calf serum. bEnd.3 cells were stimulated for 16 hours with 5 nmol/L human 
tumor necrosis factor-α (R&D Systems, Wiesbaden, Germany) before PMNs were 
added. Transmigrating PMNs were counted in a CASY cell counter (Schärfe System, 
Reutlingen, Germany).
Table 1. Transcript levels of syndecans, cytokines and collagens after MI.
Synd1 WT, sham, 
n=4
Synd1 KO, sham, 
n=5
Synd1 WT, MI, 
n=7
Synd1 KO, MI, 
n=7
MI, 7 days
Synd1
Synd2
Synd3
Synd4
MCP-1
RANTES
TNF-α
SDF-1  
MI, 14 days
Collagen Iα1 
Collagen III
tTG
1.6±0.13
0.40±0.02
0.48±0.03
0.43±0.05
0.06±0.01
0.17±0.02
0.10±0.03
0.07±0.01
0.07±0.005
0.03±0.01
0.39±0.06
N.D.
0.35±0.06
0.39±0.03
0.39±0.06
0.09±0.03
0.18±0.03
0.22±0.10
0.08±0.02
0.05±0.001
0.03±0.003
0.23±0.05
14±1.3
0.96±0.08†
1.1±0.17†
1.2±0.12†
0.36±0.08†
1.6±0.45†
1.0±0.12†
0.15±0.02†
1.2±0.06†
0.37±0.03†
0.88±0.13†
ND
0.92±0.10†
0.73±0.07†
1.0±0.16†
0.77±0.15*†
0.80±0.16†
0.98±0.21†
0.13±0.01†
2.1±0.3*†
0.68±0.07*†
0.76±0.11†
ND indicates not detectable; MCP-1, monocyte chemoattractant protein; RANTES, regulated-on-activation, normal T-
cell-expressed and -secreted chemokine; TNF, tumor necrosis factor; and SDF-1, stromal cell-derived factor 1.
*P<0.05 in Synd1 KO vs WT mice; †P<0.05 in infarcted (MI) vs sham-operated mice. 
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Transcript levels of cytokines in vivo
Transcript levels of the cytokines monocyte chemoattractant protein-1; regulated-
on-activation, normal T-cell-expressed and –secreted chemokine: tumor necrosis 
factor-α; and stromal cell-derived factor were investigated in infarcted and sham 
tissue of Synd1 KO compared with WT mice with acidic ribosomal phosphoprotein 
P0 (ARBP) as the housekeeping gene. Methodology and a list of the primers used 
are presented in online Data Supplement, Section II.
Collagen content
First, transcript levels of collagen type I and III were investigated in infarcted and 
sham hearts of Synd1 KO compared with WT mice (online Data Supplement, 
Section II). Next, collagen was stained on cardiac sections using Sirius red, and the 
amount of collagen was quantified17,18.  In addition, a microplate reader–based 
quantification of collagens was performed as described by others16,20. Previously, 
this test has been shown to be comparable to the colorimetric hydroxyproline 
assay20. Quality of collagen fibers was further investigated by Sirius red 
polarization microscopy, allowing to quantify the thick, tightly packed collagen 
fibers as orange-red, and the thin , loosely assembled fibers appearing as yellow-
green21. Ultrastructural analysis was done as described18.
tTG and MMP activity in infarcts
Zymographic activity of MMP-2 and -9 in infarcted and sham hearts was performed 
as described17,22.
Because MMP-2 is able to inactivate tTG, activity of tTG in the infarcted area 
was measured by incorporating biotinylated cadaverine into fibronectin12. 
Next, transcript levels and protein expression of tTG were measured by real-
time polymerase chain reaction (online Data Supplement, Section II) and 
immunoblotting (ab2972-500, Abcam)22. 
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Adenoviral gene transfer of Synd1
Replication deficient adenoviruses containing rat Synd1 cDNA (AdSynd1) or the 
control R5 gene17 (AdR5), both under control of the cytomegalovirus promoter, 
were generated by homologous DNA recombination in bacteria, followed by viral 
particle generation and large-scale production in HEK293 cells as described23.
Then, 100 µl of 1.0 x 109 plaque-forming units AdSynd1 or control AdR5 diluted in 
saline was injected into the tail vein of Synd1 WT mice, followed by induction of MI. 
Synd1 plasma levels were semiquantitatively measured in 100 µl blood sampled 
from the retro-orbital plexus by Synd1 immunoblotting (Sc-5632, Santa Cruz 
Biotechnology, Santa Cruz, Calif) at 7 days after gene transfer. Echocardiography 
was performed in Synd1 and control R5-treated at 14 days after MI, followed by 
histological and molecular analysis of infarcted hearts.
Figure 1. Synd1 expression 
after MI. In situ hybridization 
(A,B), immunostaining (C,D) 
and immunodot blot analysis 
(E,F) of Synd1 in infarcted 
WT hearts revealing minimal 
Synd1 expression 1 day after 
MI (A,C,E), and a progressive 
increase at 4 days (A,C,E), 
reaching its maximum at 7 
days (A-E) and decreasing 
again at 14 days (A,C,E) after 
MI, all relative to sham levels. 
Synd1 mRNA was low to absent 
in sham-operated hearts. 
Ratio of shed to total Synd1 
significantly increased in the 
infarcted myocardium at 1 and 
4 days but declined at 7 and 14 
days vs sham levels (F).   
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Echocardiographic measurements
Transthoracic echocardiography with a 12-mHz probe (Hewlett Packard, 
Amsterdam, The Netherlands) on a sonos 5500 echocardiograph (Hewlett Packard, 
Palo Alto, Calif) was performed as described before18,22.  
Statistical Analysis
Data were expressed as mean±SEM.  No repeated measures were performed. 
Echocardiographic measurements and histological and molecular analysis in 
sham-operated and infarcted groups at 7 and 14 days were all performed in 
independent groups. Normal distribution of all continuous variables was tested 
using the method of Kolmogorov and Smirnov. An unpaired t test was used most 
of the comparisons when groups passed the normality test. A Mann-Whitney test 
was used, however, when the standard deviations of 2 groups differed significantly. 
A 2-sided value of P<0.05 was considered statistically significant. 
The authors had full access to the data and take responsibility for the integrity of 
the data. All authors have read and agree to the manuscript as written.
Results
Increased expression of Synd1 after MI
In situ hybridization of Synd1 revealed minimal Synd1 mRNA expression in the 
infarcted myocardium of WT mice at 1 day after MI (n=7), with a progressive 
increase in Synd1 mRNA from 4 days (n=6) (Figure 1A), reaching its maximum at 
7 days (n=8) (Figure 1A and 1B) and decreasing again at 14 days after MI (n=10) 
(Figure 1A). Synd1 mRNA was absent in sham-operated hearts. Expression was 
located primarily in inflammatory cells, endothelial cells and (myo)fibroblasts in 
the infarcted and peri-infarct region.  
Concordant with in situ hybridization, Synd1 immunostaining and dot-blot analysis 
revealed significantly increased expression of Synd1 in the infarct region, with a 
maximal expression at day 7, again declining at day 14 (Figure 1C through E). Ratio 
of shed to total Synd1 increased significantly in the infarcted myocardium at 1 
and 4 days but declined at 7 and 14 days compared with sham levels (Figure 1F).
To investigate whether the absence of Synd1 may result in compensatory changes 
in expression of other syndecans, transcript levels of Synd1, 2, 3, and 4 were 
determined in Synd1 KO compared with WT hearts at 7 days after MI or sham 
surgery. Transcript levels of Synd2, 3, and 4 were significantly increased in WT 
and KO infarcts at 7 days after MI compared with sham hearts, concordant with 
previous findings by Finsen et al10 (Table 1). Lack of Synd1, however, did not result 
in a compensatory increase of Synd2, 3, or 4 after MI, nor did levels of Synd2, 3, or 
4 differ in sham hearts of Synd1 KO compared with WT mice (Table 1).  
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Increased recruitment of inflammatory cells in Synd1 KO mice 
Infarct size did not differ significantly between Synd1 WT and KO mice (Table 2). 
The number of CD45-immunoreactive inflammatory cells (Figure 2C and 2D, Table 
2) was significantly increased in Synd1 KO compared with WT infarcts at 7 and 
14 days. Increased inflammation in the absence of Synd1 resulted in accelerated 
replacement of injured cardiomyocytes by granulation tissue, as indicated 
by significantly decreased amount of residual myocardial necrosis, increased 
smooth-muscle cell actin-immunoreactive myofibroblasts and coronary vessels, 
and increased CD31-immunoreactive capillaries in Synd1 KO compared with WT 
infarcts at 7 days after MI (Table 2 and Figure 2A and 2B). 
Increased inflammation in the infarct was associated with significantly increased 
transcript levels of monocyte chemoattractant protein-1 (Table 1), involved in 
adverse infarct healing and increased cardiac dilatation and dysfunction after 
Figure 2. Adverse infarct wound healing in Synd1 KO mice. A, B, Hematoxylin and eosin staining revealed a higher degree 
of removal of necrotic cardiomyocytes in the Synd1 KO vs WT infarcts at 14 days. C, D, Significantly increased number of 
CD45-immunoreactive inflammatory cells at 14 days in Synd1 KO vs WT infarcts. 
Chapter 4
 65Syndecan-1 and myocardial infarction
MI24,25. Increased inflammation in Synd1 KO infarct was related to significantly 
increased adhesion and transmigration of PMNs through bEnd.3 murine 
endothelial cells in vitro in Synd1 KO compared with WT PMNs (adhesion, n=6, 
P<0.05; transmigration, n=4, P<0.001) (Figure 3A through 3D).
Together, these data show that lack of Synd1 results in increased influx of 
inflammatory cells in the infarcted myocardium with accelerated wound healing 
and reveal a direct role for Synd1 in regulating transendothelial adhesion and 
transmigration of inflammatory cells in vitro. 
Figure 3. In vitro 
experiments. 
A-C. Increased 
adhesion of 
fluorescently labeled 
PMNs to endothelial 
cells in Synd1 KO vs 
WT mice (*P<0.05).
D. Transendothelial 
migration of PMNs 
is increased in Synd1 
KO vs WT mice 
(*P<0.001).
66
Figure 4. Abnormal collagen formation in Synd1 KO infarcts. A, B, Sirius red analysis revealed significantly increased 
collagen deposition in Synd1 KO vs WT infarcts. C, D, Sirius red polarization microscopy revealed mainly well-aligned and 
thick, tightly packed (orange-red) collagen fibers in WT infarcts but loosely assembled fibers (yellow-green) predominating 
in Synd1 KO infarcts. E, F, Ultrastructural analysis confirmed a disorganized collagen matrix with a predominance of 
smaller, less qualitative collagen fibers in Synd1 KO infarcts (F) in contrast to the well-organized collagen matrix with 
uniform and sharply delineated collagen fibers in WT infarcts (E).  
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Deficient collagen maturation and organization in the absence of Synd1
Next, we investigated whether accelerated infarct healing in absence of Synd1 
affected collagen remodeling. Transcript levels of collagen type Iα1 and III and 
amount of collagen were significantly increased in Synd1 KO compared with 
WT infarcts but did not differ between sham-operated hearts (Figure 4A and 4B, 
Tables 1 and 2). Sirius red polarization microscopy revealed mainly well-aligned 
and thick, tightly packed (orange-red) collagen fibers in WT infarcts (Figure 4C). In 
contrast, loosely assembled (yellow-green) collagen fibers predominated in Synd1 
KO infarcts at 14 days (ratio of orange-red to yellow-green birefringent collagen in 
the infarct area at 14 days;  Figure 4C and 4D, Table 2).  
Ultrastructural analysis confirmed a disorganized matrix with a predominance of 
smaller and fragmented collagen fibers in Synd1 KO infarcts, in contrast to the well-
organized collagen matrix with uniform and sharply delineated collagen fibers 
in WT infarcts (Figure 4E and 4F). Thus, increased inflammation and accelerated 
infarct healing in the absence of Synd1 resulted in increased collagen deposition, 
but of impaired quality.  
Increased activity of MMPs in the absence of Synd1  
Inflammatory cells in the infarct are the main source of MMP-2 and -9, proteolytic 
enzymes involved in cardiac dilatation and dysfunction after MI16,17,26. Increased 
inflammation in the absence of Synd1 was related to significantly enhanced levels 
of pro-MMP-2 and -9 enzyme activity in Synd1 KO compared with WT infarcts at 
14 days after MI (n=5 per group; P<0.05; Figure 5A). Immunoblotting confirmed 
the identity of the proform of MMP-2 and MMP-9, and semi-quantitative analysis 
showed increased expression of pro-MMP-2 and -9 in Synd1 KO compared with 
WT infarcts (Figure 5B). Baseline pro-MMP-2 or -9 protein and activity levels did 
not significantly differ between Synd1 WT and KO mice (online Data Supplement, 
Section III). 
MMP-2 inactivates tTG12, an enzyme known to stabilize the ECM27 and protect 
against cardiac dilatation13,14. The activity level of tTG was significantly decreased 
in infarcts of Synd1 KO compared with WT mice at 14 days (n=6 per group; P<0.05; 
Figure 5C), whereas total protein levels determined by immunoblotting did not 
significantly differ (Figure 5D). Decreased tTG activity resulted in decreased 
collagen cross-linking, as suggested by a decrease in immunoreactivity of ε-lysyl 
γ-glutaminyl cross-links in infarcts12 (Figure 5 E and 5F).  Baseline protein or activity 
levels of tTG did not differ significantly in Synd1 WT compared with KO sham mice 
(online Data Supplement, Section III). Thus increased collagen fragmentation and 
cardiac dilatation in mice lacking Synd1 were related to increased MMP activity 
and decreased tTG activity. 
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Increased cardiac dilatation and systolic dysfunction in the absence of Synd1
Echocardiographic analysis revealed increased cardiac dilatation and impaired 
systolic function in Synd1 KO compared with WT infarcted hearts at 14 days (Table 
3). Increased cardiac dilatation was accompanied by significantly decreased infarct 
thickness in Synd1 KO mice (Table 3), indicating increased infarct expansion. 
Increased cardiac failure after MI in Synd1 KO mice was further confirmed by a 
significant increase of ~110 % in the ratio of lung to body weight in Synd1 KO 
compared with a nonsignificant increase of ~25 % in WT mice at 14 days after MI 
(Table 3). Heart rate did not significantly differ between both groups (Table 3).
Figure 5. Increased MMP and decreased tTG cross-linking in Synd1 KO infarcts. A, B, Significantly increased zymographic 
activity (A) and protein expression (B) of pro-MMP-2 and -9 in Synd1 KO vs WT mice at 14 days after MI. C, D, Significantly 
decreased activity (C) of tTG but unchanged protein expression (D) in infarcts of Synd1 KO vs WT mice at 14 daxys. E, 
F, Decreased collagen cross-linking in Synd1 KO, as suggested by a consistent decrease in immunoreactivity of  -lysyl 
  -glutaminyl cross-links in Synd1 KO (F) compared with WT (E) infarcts. γ
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Synd1 WT, 
sham, 14 d
n=7
Synd1 KO, 
sham, 14d
n=8
Synd1 WT, 
infarct, 14d
n=10
Synd1 KO, 
infarct, 14d
n=11
AdV R5
infarct, 14d,
n=8
AdV Synd1,
infarct, 14d
n=8
LV/BW 
ratio, mg/g
3.7 ± 0.2 3.5 ± 0.1 4.4 ± 0.2† 4.2 ± 0.3† 4.5 ± 0.1† 4.3 ± 0.2†
Lung/BW 
ratio
6.0 ± 0.6 5.9 ± 0.3 8.0 ± 0.8 13.4 ± 1.9*† 6.5 ± 0.4 7.8 ± 0.3*
PW diast., 
mm
0.73 ± 0.03 0.74 ± 0.03 0.82 ± 0.1 0.84 ± 0.08 0.81 ± 0.05 0.78 ± 0.02
SW diast., 
mm
0.82 ± 0.02 0.81 ± 0.03 0.92 ± 0.1 0.91 ± 0.07 0.93 ± 0.04 0.94 ± 0.03†
LV EDD, 
mm
4.3 ± 0.1 4.1 ± 0.2 5.5 ± 0.2† 6.6 ± 0.3*† 4.9 ± 0.03† 4.1 ± 0.2*
LV ESD, mm 3.2 ± 0.1 3.0 ± 0.1 4.6 ± 0.3† 5.6 ± 0.4† 3.8 ± 0.1 3.0 ± 0.1*
FS, % 27 ± 2.1 26 ± 2.4 18 ± 2.6† 10 ± 1.0*† 22 ± 0.8† 28 ± 1.2*
Heart rate, 
beats/min.
480 ± 31 490 ± 22 450 ± 25 470 ± 29 490 ± 20 500 ± 12
Synd1 gene overexpression prevents cardiac dilatation and dysfunction
To investigate whether overexpression of Synd1 may prevent increased cardiac 
inflammation, dilatation, and dysfunction after MI, a replication- deficient 
adenovirus overexpressing Synd1 was injected in Synd1 WT mice, resulting in an 
~30-fold increase in Synd1 immunoblotting in blood at 7 days after MI (online Data 
Supplement, Section IV).  Overexpression of Synd1 significantly reduced cardiac 
inflammation in the infarct, improved quality of collagen (Figure 6A through 6F, 
Table 2), and prevented cardiac dilatation and dysfunction at 14 days after MI 
(Table 3).  
Thus, overexpression of Synd1 clearly protects against adverse infarct healing, 
thereby reducing ventricular dilatation and failure after MI.   
AdV indicates adenovirus; AdV, adenoviral gene overexpression of a control (R5) gene compared with syndecan-1 (Synd1) 
gene; LV, left ventricular; BW, body weight; PW, noninfarcted posterior wall; diast, diastolic; SW, noninfarcted septal wall; 
EDD, end-diastolic diameter; ESD, end-systolic diameter; and FS, fractional shortening.
*P<0.05 in Synd1 KO vs WT mice and in AdV Synd1-treated vs control AdV R5-treated WT mice. 
†P<0.05 in infarcted vs sham mice. 
Table 3. Echocardiographic analysis
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Discussion
The present study unveils a novel role for Synd1 in protecting against adverse 
cardiac remodeling and dysfunction after MI.  Whereas the absence of Synd1 in 
mice resulted in accelerated infarct healing with increased cardiac dilatation and 
dysfunction after MI, adenoviral gene overexpression of Synd1 reduced cardiac 
inflammation and protected against cardiac dilatation and dysfunction after MI. 
Influx of inflammatory cells into the necrotic area is the earliest event in infarct 
healing.  These inflammatory cells degrade the extracellular matrix surrounding 
the cardiomyocytes, alter the expression and activity of growth factors and 
chemokines, and thereby clear the way for the influx of other wound healing 
cells. Expression of Synd1 is most pronounced in the periinfarct region, spatially 
and temporally related to inflammation8,9. Expression of Synd2, 3, and 4 also 
significantly increases after MI10, but lack of Synd1 did not result in compensatory 
Figure 6. Synd1 overexpression 
improves infarct healing. A, B, 
Hematoxylin and eosin staining 
revealed a lower degree of removal 
of necrotic cardiomyocytes in Synd1-
treated vs control R5-treated infarcts 
at 14 days. C, D, Significantly decreased 
number of CD45-immunoreactive 
inflammatory cells in Synd1-treated vs 
control R5-treated infarcts at 14 days. 
E, F, Increased ratio of well-aligned 
and thick, tightly packed (orange-red) 
collagen fibers to loosely assembled 
(yellow-green) fibers in Synd1-treated 
infarcts.
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changes in Synd2, 3, or 4 after MI, as observed in the present study.  
The absence of Synd1 resulted in increased cardiac inflammation and failure, 
whereas overexpression of Synd1 protected against cardiac dilatation and failure 
after MI. Increased inflammation in the absence of Synd1 resulted in increased 
expression of monocyte chemoattractant protein-1 and increased activity of 
MMP-2 and -9, factors involved in aggravating cardiac dilatation and dysfunction 
after MI15-17,24,25. Histological and molecular analyses revealed formation of 
a less qualitative collagen matrix in absence of Synd1, which was associated 
with increased MMP-2 and -9 activity and decreased tTG activity. These findings 
indicate a central role for Synd1 in regulating infarct inflammation and healing 
and in preventing cardiac dilatation and dysfunction after MI.  
Increased Synd1 may reduce cardiac inflammation after MI by functioning as 
a barrier against invading inflammatory cells. In our present in vitro study, we 
observed increased adhesion and transendothelial transmigration of leukocytes 
lacking Synd1. Previous reports (reviewed elsewhere28) demonstrated that Synd1 
decreases leukocyte-endothelial interactions by masking adhesion ligands on 
endothelial cells and by competing with chemokines that mediate recruitment 
of inflammatory cells. Of additional interest in this regard are the findings that 
Synd1 increases adhesion of inflammatory cells to collagens and limits their 
invasion into collagen gels29. 
Synd1 also may modulate matrix assembly (reviewed previously5,6). The absence of 
Synd1 resulted in the formation of less qualitative collagen fibers after MI, whereas 
overexpression of Synd1 improved collagen quality and protected against cardiac 
dilatation. Increased inflammation in infarcts of mice lacking Synd1 resulted in 
increased MMP-2 and -9 activity and decreased tTG activity, both contributing to 
abnormal collagen formation and increased cardiac dilatation and dysfunction 
after MI13,15,17. Although a downregulation of MMP-9 expression has previously 
been linked to increased Synd1 expression in myeloma cells, increased MMP 
activity in our experiments most likely resulted from increased inflammation, 
whereas decreased tTG activity may arise from increased degradation by MMP-
212. A link between increased MMP activity and changes in collagen composition 
is suggested by different studies11,14-16, revealing that thick type I collagen fibers 
are degraded by increased MMPs and replaced by fibrous interstitial deposits of 
poorly crosslinked collagen. Reduced levels of tTG also contribute to abnormal 
collagen fibrillogenesis and parallels cardiac dilatation and dysfunction13,14. tTG 
mediates the assembly of collagen monomers into fibers, which occurs in close 
association with the cell surface and involves collagen-binding ß1 integrins27. tTG 
also stabilizes the interstitial matrix by introducting ε-lysyl γ-glutaminyl cross-
links into collagens27. 
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The present study demonstrates the importance and therapeutic potential of 
Synd1 in ventricular remodeling after MI. Our observations are concordant with 
previous findings indicating a general role for glycoproteins and matricellular 
proteins in preventing adverse infarct healing and dysfunction after MI30, as 
described for osteopontin31 and thrombospondin-132. Although we show that a 
reduction in inflammation by Synd1 is a putative mechanism, the present study 
cannot definitively answer which processes modulated by Synd1 are pivotal in its 
protective role.  
Our study reveals a novel role for Synd1 in protecting against infarct healing, 
cardiac dilatation, and dysfunction after MI. Therefore, Synd1 deserves further 
investigation as a novel therapeutic tool to reduce cardiac dilatation and failure 
after MI.
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Online supplemental Section I. In situ hybridization
Primers for Synd1 were designed (forward primer: 5’-TGC GTA CAA CAG GGT ATG 
GA- 3’ and reverse primer: 5’-CCT CCC CTC CAC TCC TAG AC- 3’), that amplified a 
217 bp sequence that was cloned into pGEM-T Easy (Promega, Madison, WI). The 
cloned product was sequenced to assure its identity (ABI Prism 310, Molecular 
Genetics, Maastricht University). The plasmid DNA was purified, linearized and 
RNA sense and anti-sense probes were obtained. RNA labeling was performed by 
in vitro transcription with Digoxigenin (DIG) (Roche Applied Science). Probes were 
applied on four micrometer cardiac sections which were previously deparaffined, 
permeabilized with 25 µg/ml proteinase K (Ambion, Austin TX), acetylated with 
0.25% acetic anhydride (Merck) in 0.1M pH 8 triethanolamine (Riedel-de Haën, 
GmbH, Seeize, Germany). The slides were hybridized overnight at 50oC and the 
hybridized probe detected using an anti-DIG antibody conjugated with alkaline-
phosphatase, visualized by nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl 
phosphate (Roche Applied Science). The sense probe and RNAse pre-treatment of 
slides were used both as negative controls.
Online supplemental Section II
RNA was isolated from infarcted and sham tissue using the RNeasy Mini Kit 
(Qiagen) and stored in -80ºC. RNA was reverse transcribed into cDNA using the 
iScript™ cDNA synthesis kit (BioRad). Real-time quantitative PCR was performed 
using iQ™ SYBR green supermix (BioRad) and primers designed with Primer Express 
Software (PE Applied Biosystems, Foster City, CA). Acidic ribosomal phosphoprotein 
P0 (ARBP) was used as the housekeeping gene.
Primers used were:
Gene Forward primer 5’ –  3’ Reverse primer 5’ –  3’
Syndecan 1 CCTTTTGGACAGGAAGGAAGTG TCCTTCTTCTTCATCCGGTACAG
Syndecan 2 ACAGAAGTTCTAGCAGCCGTCATT CGGTACACCAATAGCAGGATGAG
Syndecan 3 TGCTCGTAGCCGTGATCGT GGTGTAGCTGCCTTCGTCCTT
Syndecan 4 CCCAGGGCAGCAACATCTT AGGATCAGGAAAACGGCAAA
MCP-1 ACCAGCAGCAGGTGTCCC GCACAGACCTCTCTCTTGAGCTT
RANTES TCCAATCTTGCAGTCGTGTTTG TCTGGGTTGGCACACACTTG
TNF-α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
SDF-1 TGCCGGTTCTTCGAGAGC CAGCCGTGCAACAATCTGAA
Collagen Ia1 CTTCACCTACAGCACCCTTGTG CTTGGTGGTTTTGTATTCGATGAC
Collagen III TCGGAACTGCAGAGACCTAAA CCCCAGTTTCCATGTTACAGA
tTG TGGAAGTCTCAGACCCGGTG CCAATATCAGTCGGGAACAGGT
ARBP GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
Online supplemental Section III
Baseline pro-MMP-2 or -9 zymographic activity levels did not differ significantly 
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between Synd1 KO and WT mice (arbitrary units of lysis, Spec_OD/A.U.mm²: pro-
MMP-9, 0.7 ± 0.1 in WT versus 0.6 ± 0.2 in KO mice, n=4, P=NS; pro-MMP-2, 1.5 ± 
0.3 in Synd1 KO versus 1.7 ± 0.2 in WT mice, n=4, P=NS). 
 
Baseline pro-MMP-2 or -9 protein levels did not differ significantly between Synd1 
WT and KO mice (arbitrary units: pro-MMP-9, 8 ± 1.2 in KO versus 6.8 ± 2.1 in WT 
mice, n=4, P=NS; pro-MMP-2: 4.0 ± 0.5 in Synd1 KO mice versus 4.1 ± 0.4 in WT 
mice, n=4, P=NS).
Baseline protein or activity levels of tTG did not significantly differ in Synd1 WT 
compared with KO sham mice (tTG activity in arbitrary units at 14 days: 0.11 ± 0.05 
in Synd1 WT versus 0.08 ± 0.02 in KO sham hearts; tTG protein levels in arbitrary 
units at 14 days: 0.7 ± 0.2 in Synd1 WT versus 0.8 ± 0.2 in KO sham hearts; n=4 per 
group, P=NS).
Online supplemental Section IV
Increased expression of Synd1 at 7 days after intravenous injection of a 
replication deficient adenovirus overexpressing Synd1 (AdSynd1), as revealed by 
immunoblotting (representative blot of n=3 per group).
65 kD
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Abstract
Syndecan 1 (Synd1) is a transmembrane heparan sulfate proteoglycan that 
functions as a co-receptor for various growth factors, and modulates signal 
transduction.  Recently, it has been shown that Synd1 expression increases after 
experimental myocardial infarction. Given its important role as a co-receptor we 
hypothesized that Synd1 plays a role in hypertension-induced cardiac fibrosis.
Synd1 knockout (KO) mice and their wild-type (WT) controls received angiotensin 
II (AngII) (1,5 mg/kg/day) for 14 days. After AngII infusion, systolic function was 
impaired in WT mice while Synd1 KO mice preserved systolic function (Fractional 
shortening; WT: 21.5±2.8% vs KO: 29.6±2.6%, P<0.05, n=8-14). AngII induced 
fibrosis in WT mice (1018,3±214.2% compared to WT control (100%), n=8) but 
significantly less in Synd1 KO mice (581.1±92.2%, n=15), as measured by Sirius 
Red staining and Q-PCR. In vitro, AngII and transforming growth factor ß (TGFß) 
induced connective tissue growth factor (CTGF), a mediator of AngII-induced 
fibrosis, expression in cardiac fibroblasts (CF). Knockdown of Synd1 by shRNA 
attenuated this increase of CTGF. In contrast, overexpression of Synd1 increased 
AngII mediated CTGF expression. 
We show that hypertension-induced cardiac fibrosis and dysfunction is attenuated 
in Synd1 KO mice. Furthermore, we show that Synd1 amplifies CTGF expression 
by augmenting AngII-induced TGFß signaling, thereby enhancing the profibrotic 
effects of AngII. These findings suggest that inhibition of Synd1 may be an 
attractive adjuvant strategy to limit the ability of AngII to induce cardiac fibrosis.
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Introduction
Matrix accumulation, collagen deposition and stiffening hallmark the adverse 
remodeling in chronically overloaded myocardium1. The underlying mechanisms 
are not yet fully elucidated, but neurohormones and growth factors such as 
angiotensin II (AngII), endothelin and transforming growth factor ß1 (TGFß) are 
associated with enhanced synthesis of collagens and other matrix proteins, and 
have been implicated in the development of such adverse structural changes2. 
Apart from causing high blood pressure, AngII also may initiate adverse signaling 
in the heart, thereby causing cardiac hypertrophy and cardiac fibrosis3. The 
profibrotic signaling caused by AngII is importantly mediated via activation of 
the TGFß system, and concomitant activation of connective tissue growth factor 
(CTGF) expression4,5. AngII both induces the production of TGFß, CTGF and the 
expression of endoglin, a TGFß receptor, in cardiac fibroblasts, so that blockade of 
either TGFß signaling or of CTGF effectively decreases AngII-induced fibrosis4-6. 
Syndecans are heparan sulfate proteoglycans, which are present at the cell 
membrane where they modulate cell-matrix interactions7. They can bind to 
extracellular matrix proteins, growth factors, and other cell surface proteins. This 
allows syndecans to influence cellular migration and growth factor signaling, 
like fibroblast growth factor (FGF) and TGFß signaling8-10. Also, AngII-mediated 
signaling can be modulated by heparan sulfates11. Up to date, the precise role 
of syndecans in pathological remodeling of the hypertensive heart is unknown. 
Given its involvement in signal transduction modulation, we hypothesized that 
syndecan 1 (Synd1) is involved in AngII-induced cardiac remodeling.
Here, we show that Synd1 plays a crucial role in AngII-induced cardiac remodeling. 
Synd1 KO mice are protected against AngII-induced cardiac dysfunction and 
fibrosis. These findings were confirmed in vitro, where shRNA mediated knock-
down of Synd1 significantly attenuates the ability of AngII and TGFß to increase 
CTGF expression, a known mediator of AngII-induced fibrosis. In reverse, over-
expression of Synd1 indeed increased CTGF expression. Our data show that Synd1 
is an important regulator in the development of cardiac fibrosis, and therefore 
may be a new therapeutic target in pathological forms of cardiac fibrosis.
Material and Methods
In vivo experiments
We used 14- to 20-week-old male inbred BALB/c Synd1 knockout (KO) mice and 
their wild-type (WT) littermates. Synd1 mice were a gift from M.A. Stepp, PhD, 
Washington, DC. Angiotensin II (1,5 mg/kg/day) was administered for 14 days via 
osmotic minipumps (Alzet osmotic minipumps, Palo Alto, CA, USA; types 2ML4). At 
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the end of experiment, echocardiography was performed under 2-4% isofluorane 
anesthesia, as described previously 12. Experiments were carried out according to 
the institutional guidelines for the experimental use of animals.
Measurement of myocardial collagen content
Myocardial collagen was stained with picrosirius-red as described earlier13. For 
the quantification of left ventricular collagen volume fraction (CVF), computerized 
planimetry was performed in at least 7 randomly selected fields per section per mouse.
Sham 14 days AngII
WT
n=4
KO
n=5
WT
n=8
KO
n=14
BW end (g) 31±0.4 23.2±1.0* 24.4±0.9* 20.9±0.6*†
LVW/BW 4.1±0.1 4.3±0.1 5.4±0.2* 5.1±0.2*
LW/BW 6.0±0.2 6.9±0.5 7.7±0.8 8.0±0.5
Cloning lentiviral Synd1 short hairpin RNA expressing constructs 
Small interfering RNA against Synd1 was designed by Eurogentec, Liège, Belgium. 
From this design oligo’s with one hairpin loop (shRNA) were created (table 3). The 
oligo’s were cloned into XhoI and HpaI site of the vector pLenti Lox 3.7 puro. This 
vector was modified from the pLenti Lox 3.7 14 (pll3.7puro) by replacing the eGFP 
gene by puromycin. Constructs were verified by sequencing. 
Lentiviral production was performed by co-transfection of 3 µg shSynd1/pLL3.7 
puro or empty pLL3.7puro and packaging vectors into 293FT cells by Lipofectamine 
2000 (Invitrogen) and virus-containing supernatant was harvested after 48 hours.
Adenoviral overexpression of Synd1
Replication deficient adenoviruses containing rat syndecan-1 cDNA (AdSynd1) or 
the control R5 gene (AdR5), all under control of the cytomegalovirus promoter, 
were generated and produced as described previously 15.
Cardiac fibroblast culture
Dulbecco’s modified eagle’s medium (DMEM), and fetal bovine serum (FBS) were 
purchased from GIBCO BRL, Breda, the Netherlands. Culture plates were obtained 
from Costar, Badhoevendorp, the Netherlands. Cardiac fibroblasts were isolated 
from 2-day-old neonatal Lewis rats. All the experiments were performed on cells 
from the second passage. Cells were maintained in DMEM supplemented with 10% 
FBS along with 50µg/ml gentamycin, and 100 units/ml penicillin/streptomycin, 
and were incubated at 37°C in a humidified chamber. Cells were allowed to attach, 
where after they were infected with lentivirus harboring shRNA against Synd1 
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Table 1. General parameters 
of the mice at the end of the 
study.
*P<0.05 vs corresponding sham 
or WT sham, †P<0.05 vs WT AngII
LVW: left ventricular weight, 
BW: body weight, LW: lung 
weight
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or control lentivirus, facilitated by Sequabrene (Sigma). After puromycin selection 
(3µg/ml), cells were placed in low-serum medium (0.4% FBS) for 24 hours. Synd1 
knockdown (KD) and wild type cells received AngII (1µM) or TGFß (1ng/ml) for 24 
hours. For adenoviral transfection, cells were transfected with AdR5 or AdSynd1 
for 48 hours. Hereafter, cells were placed on low-serum medium (0.4% FBS) for 24 
hours. After synchronization, cells received AngII (1µM) for 24 hours.
RNA isolation and expression
RNA was isolated from left ventricular tissue using the RNeasy Mini Kit (Qiagen) 
and stored in -80ºC. RNA was reverse transcribed into cDNA using the iScript™ 
cDNA synthesis kit (BioRad). Real-time quantitative PCR was performed using iQ™ 
SYBR green supermix (BioRad) and primers designed with Primer Express Software 
(PE Applied Biosystems, Foster City, CA). Tubulin was used as a housekeeping gene. 
Primers used are shown in table 3.
Sham 14 days AngII
WT 
n=4
KO
 n=5
WT
 n=8
KO
 n=14
FS, % 30.3±2.3 29.7±1.2 21.5±2.8* 29.6±2.6†
LVIDd, cm 4.1±0.1 3.7±0.1* 4.1±0.1 3.5±0.1†
LVIDs, cm 2.8±0.1 2.7±0.1 3.2±0.1 2.5±0.2†
IVSd, cm 0.93±0.05 0.9±0.04 1.09±0.1 1.11±0.05*
LVPWd, cm 0.92±0.06 0.9±0.04 1.1±0.02* 1.12±0.06*
Western blotting
Western blotting was performed with the specific antibodies against CTGF, total 
SMAD3 (Abcam), and phospho-SMAD3 (CST). To ensure equal loading, the same 
membranes were probed with GAPDH (RDI). Bands were visualized by enhanced 
chemiluminiscence and quantified by the program Quantity One (Bio Rad).
Statistical Analysis
The data are expressed as mean ± SEM. Data are derived from at least 2 different 
Table 2. Functional analysis of Syndecan-1 WT and KO mice 
Echocardiographical data obtained at the end of the study. FS, fractional shortening; LVIDd, left ventricular diameter 
diastole; LVIDs, left ventricular diameter systole; IVSd, intraventricular septum diastole; LVPWd, left ventricular posterior 
wall diastole. 
*P<0.05 vs corresponding sham or WT sham, †P<0.05 vs WT AngII
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experiments performed in triplicate. Statistical analysis was performed using the 
Student t test. Differences between the groups were considered to be significant 
when P ≤ 0.05.
Results
Synd1 KO mice are protected against AngII-induced cardiac dysfunction
To investigate the involvement of Synd1 in AngII-induced cardiac dysfunction, 
we treated Synd1 WT and KO mice with AngII for 2 weeks. AngII treatment 
resulted in cardiac hypertrophy in both Synd1 WT and Synd1 KO mice (table 1). 
Figure 1. Cardiac fibrosis after AngII treatment 
is significantly attenuated in Synd1 KO mice as 
compared to Synd1 WT mice. A, representative Sirius 
Red staining of a Synd1 WT mouse treated with AngII. 
B, representative Sirius Red staining of a Synd1 KO 
mouse treated with AngII. C, Quantification of Sirius 
Red staining. *P<0.05, n=4-5 in sham mice, n=9-14 in 
AngII treated mice.
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Echocardiographic analysis at the end of the study revealed a significantly better 
systolic function in the Synd1 KO mice treated with AngII, as compared to the 
AngII-treated WT mice (Fractional Shortening, KO; 29,6±2.6 vs. WT; 21,5±2.8, n=8-
14, P<0.05, table 2). 
Cardiac fibrosis is attenuated in Synd1 KO mice after AngII infusion
Quantification of total collagen with a computer-assisted densitometric analysis 
showed a significantly increased collagen content after AngII treatment, in both 
Synd1 KO and WT mice, as compared to placebo treated mice. However, Synd1 
KO mice display significantly less collagen then WT mice after AngII treatment 
(581.1±92.2% vs 1018.3±214.2%, respectively, P<0.05, SR staining compared to 
WT sham (100%), Figure 1). These findings were confirmed by mRNA expression of 
collagen I, collagen III, and CTGF in the left ventricle, as measured by Q-PCR (Figure 2). 
 
 
Figure 2. Col1, Col3, and CTGF transcript levels as 
measured by Q-PCR. A, Quantification of Col1 transcript 
levels. B, Quantification of Col3 transcript levels. C, 
Quantification of CTGF transcript levels. *P<0.05, n=3 in 
sham mice, n=5-10 in AngII treated mice.
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Synd1 is essential for optimal CTGF expression after AngII or TGFß stimulation in 
cardiac fibroblasts
Since we showed that Synd1 is important in the development of cardiac fibrosis 
in vivo, we investigated how Synd1 may influence profibrotic signaling in vitro. 
Using lentiviral-mediated shRNA against Synd1, we knocked-down Synd1 in 
cardiac fibroblasts (80% decrease in Synd1 levels, data not shown), and examined 
the expression of CTGF after AngII or TGFß stimulation. As expected, CTGF 
expression in cardiac fibroblasts increased after 24 hours of AngII or TGFß in 
control cells, as shown by Western blotting. This increase in CTGF expression was 
significantly attenuated by Synd1 knockdown (Figure 3).  In agreement, adenoviral 
overexpression of Synd1 exaggerated the expression of CTGF after 24 hours of AngII 
stimulation, again indicating that Synd1 augments CTGF expression (Figure 5). 
Gene Fw primer 5’ –  3’ Rev primer 5’ –  3’
Collagen1 CTTCACCTACAGCACCCTTGTG CTTGGTGGTTTTGTATTCGATGAC
Collagen3 TCGGAACTGCAGAGACCTAAA CCCCAGTTTCCATGTTACAGA
CTGF CACAGAGTGGAGCGCCTGTTC GATGCACTTTTTGCCCTTCTTAATG
Tubulin TGAGGGAAATCGTGCACATC ATCGCTTATCACCTCCCAGAAC
ShRNA Syndecan-1
Fw GACTTCACCTTTGAAACATTTCAAGAGAATGTTTCAAAGGTGAAGTCTTTTTC
Rev TCGAGAAAAAGACTTCACCTTTGAAACATTCTCTTGAAATGTTTCAAAGGTGAAGTC
Synd1 modulates SMAD phosphorylation after AngII or TGFß treatment in cardiac 
fibroblasts
AngII and TGFß are known to induce profibrotic signaling by recruiting SMAD 
signaling 16-18. Accordingly, Synd1 knockdown and control cardiac fibroblasts were 
treated with AngII (1µM) or TGFß (1ng/ml) for 24 hours, and the effects on SMAD 
signaling were investigated. Interestingly, loss of Synd1 significantly attenuated 
the increase in SMAD3 phosphorylation after AngII stimulation (Figure 4A). 
Also, SMAD3 phosphorylation was significantly attenuated in Synd1 knockdown 
fibroblasts after 24 hours of TGFß (1ng/ml) (Figure 4B).
Table 3. Primers and shRNA sequence 
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Discussion
The main finding of this study is that Synd1, a heparan sulfate proteoglycan, is 
an important amplifier of AngII-mediated cardiac dysfunction and fibrosis. This 
demonstrates for the first time that Synd1 is involved in pathological hypertrophic 
cardiac remodeling. Synd1 KO mice are protected against AngII-induced cardiac 
dysfunction and cardiac fibrosis, and loss of Synd1 attenuates the effect of AngII 
on Col1 and CTGF mRNA expression in vivo.  In vitro, loss of Synd1 also attenuated 
the induction of CTGF by AngII or TGFß. Synd1 seems important to promote 
SMAD3 signaling as loss of Synd1 reduced the capability of AngII and TGFß to 
induce phosphorylation of SMAD3, an important pro-fibrotic downstream effector 
of TGFß signaling. These findings substantiate the idea that Synd1 acts as a co-
receptor on the cell membrane. We speculate that Synd1 increases the efficiency 
for growth factor signaling by recruiting additional growth factors to its relevant 
receptors, thereby influencing signal transduction.
Figure 3. Effects of AngII (1μM, 
24 hours) or TGFß (1ng/ml, 24 
hours) treatment on CTGF protein 
expression in Synd1 wild-type 
(WT), and Synd1 knockdown (KD) 
cardiac fibroblasts. 
A. representative Western blot 
showing that CTGF levels are 
significantly increased after AngII 
treatment in Synd1 WT cardiac 
fibroblasts, whereas knockdown 
of Synd1 significantly attenuates 
this increase. 
B. representative Western blot 
showing that CTGF levels are 
significantly increased after TGFß 
treatment in Synd1 WT cardiac 
fibroblasts, whereas knockdown 
of Synd1 significantly attenuates 
this increase. *P<0.05, n=3 per 
experiment, quantification of 3 
experiments.
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Synd1 amplifies the induction of CTGF
CTGF is a member of CCN family proteins that induce cell adhesion, migration, 
proliferation and synthesis of collagen and other ECM proteins19. CTGF is 
over-expressed in various fibrotic disorders such as renal fibrosis, myocardial 
infarction, and atherosclerosis20,21,22. Moreover, it has been shown that CTGF is 
a crucial regulator of AngII-induced fibrosis4,23. In agreement with these reports, 
we observed an increased CTGF expression in the myocardium of mice treated 
with AngII, which was paralleled by increased cardiac fibrosis. In vitro, we also 
confirmed that AngII can effectively induce CTGF expression, as shown previously 
both in vitro and in vivo4.  Our study shows that Synd1 has an important role in this 
effect.  In vivo, AngII mediated induction of CTGF is blunted in Synd1 KO mice. This 
was paralleled by decreased induction of Col1 and Col3 mRNA by AngII in these 
Synd1 KO mice. In vitro, these findings were confirmed as the induction of CTGF by 
AngII was impaired by knockdown of Synd1. This strongly suggests that Synd1 is 
important in vivo to enable AngII to recruit CTGF. We also were able to explore how 
Synd1 enables the recruitment of CTGF. AngII might recruit CTGF via its ability to 
Figure 4: Effects of AngII (1μM, 24 hours) 
or TGFß (1ng/ml, 24 hours) on SMAD3 
phosphorylation in Synd1 WT and Synd1 
KD cardiac fibroblasts. 
A. Representative Western blot showing 
that SMAD3 phosphorylation levels 
are significantly increased in Synd1 
WT cardiac fibroblasts after AngII 
treatment, whereas knockdown of Synd1 
significantly attenuates this increase. 
B. Representative Western blot showing 
that SMAD3 phosphorylation levels 
are significantly increased in Synd1 
WT cardiac fibroblasts after TGFß 
treatment, whereas knockdown of 
Synd1 significantly attenuates this 
increase.  *P<0.05, n=3 per experiment, 
quantification of 2 experiments.
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activate TGFß and concomiting SMAD signaling. We indeed show that AngII and 
TGFß induced SMAD3 phosphorylation in cultured fibroblasts. Importantly, this 
induction is decreased by knockdown of Synd1. These findings suggest that Synd1 
serves to improve the ability of AngII and TGFß to activate SMAD3, which then can 
induce the profibrotic molecule CTGF, thereby activating Col1 expression. 
Role of Synd1 as a modulator of cell signaling
Our study shows that Synd1 has an important role as a mediator of AngII signaling. 
Syndecans are intriguing molecules, which seem to combine two major properties. 
Firstly, they contain an extracellular ectodomain with attached glycosaminoglycan 
(GAG) chains. This extracellular domain can be regarded as a ‘sticky’ part protruding 
into the ECM where it may trap signaling molecules and guide them to receptors 
on the membrane 24. Secondly they contain a transmembrane domain with a short 
cytoplasmic tail, which may serve to promote signals directly intracellularly. They 
therefore seem to be able to act both as matricellular protein in the ECM yet at 
the same time may also have transmembrane functions 25. Synd1 has been shown 
to regulate bFGF dependent signalling, and, recently, Hayashida et al. showed its 
involvement in TGFß dependent signalling 26,27. Also, heparan sulfates are able to 
regulate AngII-mediated signalling 11. Our results show that decreased expression 
of Synd1 decreases CTGF expression in cardiac fibroblasts after AngII or TGFß 
stimulation, whereas overexpression of Synd1 has the opposite effect. Whether 
this response is dependent on signalling occurring through the cytoplasmic domain 
of Synd1, or on the Synd1 ectodomain, the ‘sticky’, extracellular part of Synd1 
remains to be elucidated. Increasing ligand-receptor affinity may be a plausible 
explanation, and it is intuitive to surmise that Synd1 may function to increase the 
amount of TGFß that is presented at its receptors. TGFß is a profibrotic cytokine 
that is importantly involved in AngII- induced fibrosis. However, it is possible that 
Figure 5: Effects of AngII treatment (1μM, 
24 hours) on CTGF expression in Synd1 WT 
and Synd1 overexpressing cardiac fibroblasts. 
Representative Western blot showing that CTGF 
levels are significantly increased in Synd1 WT 
cardiac fibroblasts, whereas overexpression of 
Synd1 significantly exaggerates this increase. 
*P<0.05, n=3 per experiment, quantification of 2 
experiments.
Syndecan-1 and cardiac fibrosis
90
the effects do not rely on increased TGFß being recruited to its receptors. Recently, 
Wang et al. showed that AngII may phosphorylate SMAD3 independent of TGFß 
in vascular smooth muscle cells28.  Interestingly, our results indicate that absence 
of Synd1 also influences TGFß-induced CTGF expression, suggesting that Synd1 
interferes with AngII-induced cardiac fibrosis by modulating TGFß signaling. In 
conclusion, the present study is the first to suggest that Synd1 regulates AngII–
induced cardiac fibrosis by its ability to enhance profibrotic SMAD signalling 
culminating in increased levels of profibrotic molecules like CTGF and ultimately 
in increased expression of collagens. Our findings emphasize the important role 
of syndecans in modulating cellular signalling, and highlight Synd1 as a potential 
target for anti-fibrotic treatments.
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Abstract
Imatinib specifically inhibits receptor tyrosine kinase signaling and is clinically used 
to treat leukemia. Receptor tyrosine kinases not only mediate tumour growth, but 
also initiate adverse signaling in heart failure. We investigated whether imatinib, 
by inhibiting the platelet-derived growth factor receptor-ß (PDGFRß), prevents 
cardiac and renal damage in TGR(mRen2)27 (Ren2) rats. 
Eight-week-old male homozygous Ren2 and Sprague Dawley rats were treated 
either with imatinib (30 mg/kg; STI-571) or placebo for 8 weeks (Ren2 n=12 for 
each group; Sprague Dawley n=6 for each group). Imatinib did not affect blood 
pressure or left ventricular (LV) hypertrophy in both groups. Imatinib attenuated 
the decline in fractional shortening (imatinib versus Ren2 placebo 45±4.5% versus 
32±3%; n=7-11, P<0.05) and in diastolic function in Ren2 rats (baseline diastolic 
dP/dt corrected for systolic blood pressure Ren2 imatinib versus Ren2 placebo, 
38.6±0.67 versus 35.3±0.41 [1⋅s-1]; n=7-11; P<0.05). This was associated with 
decreased cardiac fibrosis and decreased activation of PDGFRß and extracellular 
signal-regulated kinase 1/2. Renal microvascular hypertrophy and perivascular 
fibrosis in Ren2 rats were significantly decreased by imatinib. In vitro, imatinib 
blocked angiotensin II-induced activation of the PDGFRß and significantly 
decreased fibroblast proliferation and collagen production. 
In conclusion, imatinib did not affect LV hypertrophy but attenuated the decline 
in cardiac function and reduced renal microvascular damage associated with 
reduced activation of the PDGFRß. The simultaneous improvement in both heart 
and kidneys suggests that inhibition of the PDGFRß has broad protective effects 
that may provide novel avenues for a blood pressure-independent protection 
against end-organ damage. 
Keywords: End organ damage, PDGF receptor, angiotensin II, hypertrophy, fibrosis
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Introduction
Angiotensin II (AngII) mediated hypertension causes end-organ damage not 
only via increased blood pressure, but also via the direct effects of AngII. AngII is 
known to play a crucial role in the development of cardiomyocyte hypertrophy1,2 
and interstitial cardiac fibrosis3,4, and sustained increases of AngII result in 
severe left ventricular (LV) dysfunction5-7. We have shown that the homozygous 
hypertensive TGR(mRen2)27 (Ren2) rat, a model of AngII-driven hypertension, 
develops accelerated heart failure accompanied by severe LV dysfunction and 
cardiac collagen accumulation8,9. AngII-mediated cardiac hypertrophy in Ren2 
rats is associated with increased extracellular signal-regulated kinase (ERK) and 
Smad signaling7. ERK1/2 is an important downstream target of receptor tyrosine 
kinases, like the epidermal growth factor receptor (EGFR) and the platelet -derived 
growth factor receptors (PDGFRs). Recently, AngII-mediated transactivation of 
these receptor tyrosine kinases has gained much interest10, and we demonstrated 
that inhibition of the EGFR attenuates ERK1/2 activation in the Ren2 rat, which was 
paralleled by decreased cardiac fibrosis7. Imatinib mesylate (Gleevec), a specific 
tyrosine kinase inhibitor, is a novel, orally active drug used to treat chronic myeloid 
leukaemia11. Imatinib blocks the continuously increased tyrosine kinase activity 
of bcr/abl. Bcr/abl is a fusion protein resulting from a translocation between 
chromosome 9 and 22, which is the causative gene defect in chronic myeloid 
leukemia. However, imatinib blocks other tyrosine kinases as well, including 
the tyrosine kinase activity of the PDGFRα, PDGFRß, and c-kit11. We therefore 
hypothesized that imatinib-mediated inhibition of PDGFRß tyrosine kinase activity 
may attenuate downstream ERK1/2 activation, thereby protecting against the 
direct adverse effects of AngII such as cardiac and renal fibrosis or dysfunction. 
The present study reveals that imatinib treatment in Ren2 rats protected against 
adverse cardiac and renal remodelling and dysfunction, associated with a decrease 
in PDGFRß phosphorylation and ERK1/2 activation. In concordance, administration 
of imatinib in vitro decreased collagen production and proliferation of cardiac 
fibroblasts and attenuated AngII-induced PDGFRß phosphorylation. In conclusion, 
imatinib treatment might provide a novel therapeutic tool to protect against 
cardiac dysfunction during AngII-mediated hypertension.
Material and Methods
Drug Treatment
Homozygous Ren2 and Sprague Dawley rats were purchased from the Moellegaard 
Breeding Company, Ry, Denmark. All described study protocols were approved 
by the animal care and use committee of the Universiteit Maastricht and were 
performed according to the official rules formulated in the Dutch law on care 
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and use of experimental animals. At 8 weeks of age, 24 male Ren2 rats and 12 
nontransgenic Sprague Dawley rats were randomly assigned to receive placebo 
treatment (distilled water) or imatinib dissolved in distilled water (Novartis 
pharmaceuticals; 30 mg/kg/day; Ren2 n=12; Sprague Dawley n=6 per group). 
Daily treatment via oral gavage started at the age of 8 weeks and continued until 
the age of 16 weeks.
Echocardiographical Analysis
After sedation with 2 % isoflurane, echocardiographical measurements were 
performed at day –1 (age 8 weeks), day 28 (age 12 weeks), and day 56 (age 16 
weeks, end study). Standard views were obtained in 2D as well as M-mode by 
transthoracic echocardiography with a 12-MHz transducer (Hewlett Packard) on a 
Sonos 5500 (Hewlett Packard) echocardiograph.
Functional Assessments
Rats were anesthetized with urethane (1,5 g/kg IP) at 16 weeks. The right carotid 
artery was cannulated with a 2F Millar microtip catheter and advanced into the 
left ventricle. The data were amplified, digitally stored and analyzed with IdeeQ 
(IDEE; Maastricht University). The 0-pressure baseline was obtained by placing the 
pressure sensor in 37°C water before measurements. After a period of stabilization, 
maximal LV systolic pressure, diastolic pressure, and heart rate were recorded. The 
systolic dP/dt and diastolic dP/dt were corrected for peak systolic LV pressure and 
used as indices of contraction and relaxation. 
Parameter SD pl SD ima R2 pl R2 ima
Body Weight, gr. 452±14 405±21 319±14 *‡ 325±12 *‡
LVW/Tibia Length 25±0.5 27±1.8 33±1.3 *‡ 34±1.4 *‡
Heart Rate, bpm 297±18 315±27 304±10 340±5
Fractional Shortening, % 39±1.9 44.5±1.7 32.4±3 ‡ 45.1±4.5 †
Ejection Fraction, % 74.2±2.4 80.5±1.7 64.1±4.8 ‡ 79.4±3.9 †
+ Dp/Dt / Sys 47.7±5.4 69.7±10.3 57.6±0.94 53.6±1.3
- Dp/Dt / Sys 52.8±5.8 53.4±0.82 35.3±0.41 *‡ 38.6±0.67 *†‡
Table 1. General Characteristics
General characteristics of the rats at the end of the study (16 wks of age). *P<0.05 vs. SD pl, † P<0.05 R2 pl vs R2 ima, ‡ 
P<0.05 vs Sprague Dawley ima; n = 4-6 (Sprague Dawley); n = 7-11 (Ren2).
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Histological Analysis
Rats were euthanized at 16 weeks. After perfusion with PBS, hearts and 
kidneys were taken out and prepared for further histological analysis. One half 
transverse midsection of the left ventricle and renal tissue were immersed in 1% 
paraformaldehyde for 4 to 6 hours, washed 3 times with PBS, and placed in 70% 
ethanol for 24 hours, after which it was embedded in paraffin. LV sections were cut 
at 6 µm and stained with Sirius Red to visualize collagen12. LV interstitial collagen 
was quantified by computerized planimetry. Transversal renal sections of 2 µm 
were cut for investigation of glomerulosclerosis using periodic acid staining. Renal 
sections were cut at 4 µm and stained with α-smooth muscle actin and Sirius Red 
to investigate the renal microcirculation and to stain for collagen. The percentage 
of glomeruli that exhibited focal or global glomerulosclerosis was determined as 
described previously13. Tubulointerstitial injury was defined as inflammatory cell 
infiltrates, tubular dilation or atrophy, or interstitial fibrosis. Injury was graded 
according to Shih et al14 on a scale of 0 to 4 (0 normal; 0.5 small focal areas of 
damage; 1 involvement of <10% of the cortex; 2 involvement of 10 to 25% of the 
cortex; 3 involvement of 25 to 75% of the cortex; 4 extensive damage involving 
>75% of the cortex).
Protein Isolation, Western Blotting, and Immunoprecipitation
Protein was isolated after grinding frozen heart tissue with radioimmuno-
precipitation assay (RIPA) buffer containing PBS, pH 7.4, Igepal (1%), deoxycholic 
acid (0.5%), sodium dodecyl sulfate (1%), 2-mercapto-ethanol, and complete 
protease inhibitor tabs (Roche Diagnostics). 
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Figure 1. Systolic blood pressure. Homozygous 
Ren2 rats show severe hypertension throughout 
the study as measured by tail-cuff.  Imatinib 
treatment did not affect systolic blood pressure. 
*P<0.05, Ren2 groups vs Sprague Dawley groups, 
n = 3-6.
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Western blotting15 was performed on cultured fibroblasts to identify pPDGFRß751 
PDGFRß, pEGFR1068, and EGFR (CST). Tyrosine phosphorylation state of PDGFRß (CST) 
and ERK1/2 (CST) in the heart homogenates was assessed by immunoprecipitation 
with an immobilized phosphotyrosine antibody (CST). 
Protein samples were incubated with an immobilized phosphotyrosine antibody 
(1:10) at 4ºC overnight. Subsequently, the samples were centrifuged at 2000 rpm, 
4ºC, and washed 3 times with RIPA buffer. Finally, the samples were prepared for 
Western blotting.
Cell Culture 
DMEM and FBS were purchased from GIBCO BRL. Culture plates were obtained 
from Costar. Cardiac fibroblasts were isolated from 2-day-old neonatal Lewis 
rats. All the experiments were performed on cells from the second passage. 
Cells were maintained in DMEM supplemented with 10% FBS along with 0.1% 
gentamycin, incubated at 37°C in a humidified chamber, and grown to confluence, 
before synchronization in low-serum medium (0.1% FBS) 48 hours before the 
experiments. For DNA synthesis determination, cells were put on high (10% FBS) 
or left on low (0.1% FBS) serum for 24 hours after 30 minutes pretreatment with 
increased concentrations of imatinib (0 to 10 µmol/L). Synthesis of DNA was 
assessed by radiolabeled [3H]thymidine incorporation assay. For collagen synthesis 
determination, cells were treated with imatinib (control 1 and 10 µmol/L) for 24 
hours. Hereafter, [3H]proline was added for 48 hours. The incorporated [3H]proline 
was corrected for cell density by dividing the radioactivity in disintegrations per 
minute by the total amount of cellular proteins. 
For transactivation experiments, cardiac fibroblasts were treated with imatinib or 
placebo 30 minutes before the addition of AngII (1µmol/L), PDGF-BB (20ng/mL) or 
EGF (10ng/mL). One minute or 10 minutes after growth factor stimulation, cells 
were harvested and prepared for Western blotting.
Statistical analysis
Data are presented as means ± S.E.M. Statistical analysis was performed using 
paired and unpaired Student t test.
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Figure 2. Effect of imatinib treatment 
on afferent arterioles cross sectional 
area, lumen and perivascular 
fibrosis.
A. Quantification of medial cross-
sectional area of afferent arterioles 
in Sprague Dawley, untreated 
and imatinib treated Ren2 rats. 
Imatinib treatment reversed media 
hypertrophy in homozygous Ren2 
rats. *P<0.01; †P<0.001; n= 7.
B. Lumen diameter of afferent 
arterioles in Sprague Dawley, 
untreated, and imatinib-treated 
Ren2 rats shows no significant 
differences. 
C. Imatinib treatment decreased 
perivascular fibrosis of afferent 
arterioles correlated with their lumen 
diameter in Ren2 rats. *P<0.01.
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Results
Imatinib does not lower blood pressure but improves hemodynamics in the Ren2 rat 
After 8 weeks of treatment, body weight was significantly lower in the Ren2 groups 
compared with the Sprague Dawley groups, but imatinib did not significantly alter 
body weight (Table). LV to body weight ratio was significantly increased in Ren2 
rats compared with Sprague Dawley rats and was not altered by imatinib (Table). 
Ren2 rats had severely elevated blood pressures. Imatinib did not affect systolic 
blood pressure (Figure 1).
To assess cardiac function of the rats during the study, we performed echo-
cardiography as described above. In placebo-treated rats, fractional shortening 
decreased significantly. Imatinib significantly attenuated this decrease (Table). 
After 8 weeks of treatment, baseline diastolic dP/dt was significantly higher in 
imatinib treated Ren2 rats compared to placebo-treated Ren2 rats (Table). Imatinib 
treatment had no significant effects in Sprague Dawley rats (Table).
Imatinib decreases cardiac interstitial fibrosis in Ren2 rats 
Heart sections were stained with Sirius Red to visualize total collagen. 
Quantification of myocardial collagen with a computer-assisted densitometric 
analysis revealed a significant decrease in interstitial collagen content in Ren2 rats 
treated with imatinib compared with placebo-treated Ren2 rats (4.6±0.3% versus 
5.5±0.3%, respectively; P<0.05).
Imatinib decreases renal microcirculatory changes in Ren2 rats 
Renal afferent arterioles of Ren2 rats showed significant thickening of the vascular 
wall and a nonsignificant tendency toward a larger lumen (Figure 2). Imatinib fully 
prevented vascular thickening and normalized vascular thickness. Perivascular 
collagen was markedly increased in afferent arterioles of untreated rats, which 
was significantly decreased by imatinib treatment (Figures 2 and 3).
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Imatinib attenuates glomerular and tubular damage in Ren-2 rats
Tubular atrophy was markedly attenuated by imatinib (1.7±0.4 R2pl versus 0.8±0.3 
R2ima; n=7; P<0.05), whereas glomerulosclerosis index decreased nonsignificantly 
(0.6±0.2 R2pl versus 0.3±0.1 R2ima) after imatinib in Ren2 rats (Figure 3). 
Glomeruli of Ren2 rats showed a slightly increased mesenchymal damage as 
semiquantitatively investigated, which was downregulated towards control level 
in imatinib-treated rats (0.5±0.1 R2pl versus 0.3±0.1 R2ima; n=7; P<0.05; Figure 3).
Imatinib decreases cardiac fibroblast collagen production and proliferation in vitro
Collagen production by cardiac fibroblasts, measured by [3H]proline incorporation, 
was significantly reduced by imatinib (Figure 4A). 
Proliferation of neonatal rat cardiac fibroblasts on 10% FBS was dose-dependently 
inhibited by imatinib as determined by [3H]thymidine incorporation (Figure 4B, 
black bars). Proliferation of neonatal rat cardiac fibroblasts on 0.1% FBS was 
significantly inhibited by 0.1 to 10 µmol/L imatinib (Figure 4B, grey bars). 
Figure 3. Decreased perivascular fibrosis and renal damage 
in Ren2 rats treated with imatinib.
A. Representative Sirius Red staining of an imatinib-treated 
Ren2 rat. B. Representative Sirius Red staining of a placebo-
treated Ren2 rat.
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Imatinib attenuates PDGFR signaling 
To assess the phosphorylation state of the PDGFRß and its downstream 
signaling protein ERK1/2 in LV homogenates, we immunoprecipitated proteins 
phosphorylated on their tyrosine residues and then immunoblotted for the 
PDGFRß and for ERK1/2. Phosphorylation of the PDGFRß was increased in Ren2 
rats, but was significantly blunted by imatinib treatment (Figure 5A).  Activation of 
ERK1/2 is dependent on threonine and tyrosine phosphorylation. Imatinib reduced 
tyrosine phosphorylation of ERK1/2, a downstream signaling protein in the PDGF 
pathway (Figure 5B). 
Figure 4.  Effects of imatinib on DNA and collagen synthesis 
in cultured cardiac fibroblasts.
A, synchronised cardiac fibroblasts were treated with 
imatinib (1 to 10 μmol/L), and [3H]proline was added for 
48 hours followed by scintillation counting. Untreated cells 
were used as controls. *P<0.05 vs control; n=3.
B, Synchronised cardiac fibroblasts were treated with 
imatinib (0.001 to 1000 μmol/L) for 24 hours, and DNA 
synthesis was assessed with [3H]thymidine incorporation 
followed by scintillation counting. (black bars 10% FBS; 
grey bars 0.1% FBS) *P<0.01, †P<0.001 vs. control; n= 6. 
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Imatinib inhibits transactivation of receptor tyrosine kinases
We examined whether phosphorylation of the PDGFRß or EGFR is increased in 
cardiac fibroblasts treated with AngII, PDGF-BB or EGF. AngII treatment for 1 minute 
resulted in both PDGFRß and EGFR phosphorylation, with imatinib only inhibiting 
PDGFRß phosphorylation (Figure 6A and 6B). Ten minutes of PDGF-BB treatment 
resulted in a marked increase in both PDGFRß and EGFR phosphorylation. In 
contrast, EGF treatment only activated the EGFR, but not the PDGFRß. Imatinib 
inhibited the PDGF-BB induced effects, but not the EGF induced phosphorylation 
of the EGFR (Figures 6C through 6F).
Discussion
The present study reveals that imatinib (Gleevec), a tyrosine kinase receptor 
blocker used to treat leukemia, attenuates the loss of cardiac function in a model 
of AngII-driven hypertensive LV hypertrophy. Furthermore, imatinib improved 
renal microvascular damage in these hypertensive homozygous Ren2 rats. This 
Figure 5. Effects of imatinib treatment 
on tyrosine phosphorylation levels of 
PDGFRß and ERK1/2 in Ren2 rats. Tyrosine 
phosphorylation levels of PDGFRß 
and ERK1/2 are increased in Ren2 rats 
compared with Sprague Dawley rats. 
Imatinib treatment decreased the tyrosine 
phosphorylation levels of PDGFRß and 
ERK1/2 in Ren2 rats. A. Top, Representative 
blots showing tyrosine phosphorylation 
state of PDGFRß in Sprague Dawley (lanes 
1 and 2), untreated (lanes 3 through 8), and 
imatinib-treated (lanes 9 through 14) Ren2 
rats. Bottom, Quantification of blots from 
2 experiments, corrected for total PDGFRß 
*P<0.05; †P<0.01. B. Top, Representative 
blots showing tyrosine phosphorylation 
state of ERK1/2 in Sprague Dawley (lanes 1 
and 2), untreated (lanes 3 through 8), and 
imatinib- treated (lanes 9 through 14) Ren2 
rats. Bottom, Quantification of blots from 
2 experiments, corrected for total ERK1/2, 
*P<0.05. WB indicates Western blot.
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confirms that inhibition of growth factor signaling, such as specifically provided 
by imatinib, might represent a novel therapy to protect against cardiac and renal 
dysfunction in AngII-mediated hypertension.
Imatinib attenuated the loss of cardiac function in Ren2 rats as measured by 
echocardiography and direct LV pressure measurements. Furthermore, imatinib 
attenuated the accumulation of interstitial collagen in the heart and the kidney, 
reversed renal microvascular hypertrophy, and markedly reduced perivascular 
fibrosis in the renal microcirculation. To a smaller degree glomerular, and, in 
particular, mesenchymal and tubular, damage were attenuated by imatinib. 
The improvement in cardiac function and architecture in imatinib-treated Ren2 
rats was associated with decreased cardiac PDGFRß-ERK1/2 signals. Apart from 
a general decreased collagen content in the heart, we were further able to 
distinguish an effect on renal perivascular collagen content, which may imply 
vascular localized action of imatinib. These in vivo findings were corroborated by 
the action of imatinib in vitro on fibroblasts where it inhibited collagen production 
and fibroblast proliferation. These findings substantiate the idea that targeted 
inhibition of growth factor systems, in particular tyrosine kinase inhibition, may 
have beneficial effects in hypertensive cardiac and renal damage16. 
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Figure 6. Effects of imatinib treatment on PDGFRß and EGFR phosphorylation in AngII-, PDGF-BB-, or EGF-treated 
neonatal rat cardiac fibroblasts. A: Representative blot showing that AngII treatment (1 μmol/L; 1 minute) increased 
PDGFRß phosphorylation in cardiac fibroblasts. Treatment with imatinib (10 μmol/L) 30 minutes before AngII blocked 
induced PDGFRß phosphorylation; *P<0.05; lanes 1 and 2, control (n=3); lanes 3 and 4, AngII (n=3); lanes 5 and 6, 
AngII + imatinib (ima; n=3). B: Representative blot showing that AngII treatment (1 μmol/L; 1 minute) increased EGFR 
phosphorylation in cardiac fibroblasts. Treatment with imatinib (10 μmol/L) 30 minutes before AngII did not block 
induced EGFR phosphorylation; *P<0.05.  Left lane, control (n=3); middle lane, AngII (n=3); right lane, AngII + ima (n=3). C: 
Representative blot showing that PDGF-BB treatment (20 ng/mL; 10 minutes) increased EGFR phosphorylation in cardiac 
fibroblasts. Treatment with imatinib  (10 μmol/L) 30 minutes before PDGF-BB blocked induced EGFR phosphorylation; 
*P<0.05. Lanes 1 and 2, control (n=2); lanes 3 and 4, PDGF-BB (n=2); lane 5 and 6, PDGF-BB + ima (n=2). D: Representative 
blot showing that PDGF-BB treatment (20 ng/mL; 10 minutes) increased PDGFRß phosphorylation in cardiac fibroblasts. 
Treatment with imatinib  (10 μmol/L) 30 minutes before PDGF-BB blocked induced PDGFRß phosphorylation; *P<0.05. 
Lanes 1 and 2, control (n=2); lanes 3 and 4, PDGF-BB (n=2); lanes 5 and 6, PDGF-BB + ima (n=2). E: Representative blot 
showing that EGF treatment (10 ng/mL; 10 minutes) increased EGF phosphorylation in cardiac fibroblasts. *P<0.05. Left 
lane, control (n=2); right lane, EGF (n=2). F: Representative blot showing that EGF treatment (10 ng/mL; 10 minutes) did 
not increase PDGFRß phosphorylation in cardiac fibroblasts. *P<0.05. Left lane, control (n=2); right lane, EGF (n=2). WB 
indicates Western blot.
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Effects of imatinib in an AngII driven model of cardiac hypertrophy and failure 
Homozygous Ren-2 rats have sustained local activation of the renin-angiotensin 
system, resulting in severe hypertension17. The elevated levels of AngII may directly 
or indirectly activate growth factor systems that can be inhibited by imatinib. First, 
AngII, by binding to its AngII type I receptor, can transactivate receptor tyrosine 
kinases, including the PDGFRß10,18. The concept of transactivation by AngII has been 
reported in vitro19,20 and in vivo7,21,22. Here, we show that a 1-minute stimulation 
with AngII results in PDGFRß phosphorylation in neonatal cardiac fibroblasts, and 
that this transactivation can be inhibited by imatinib treatment. These findings 
suggest that imatinib efficiently blocks the activation of the PDGFRß in vitro as 
well and may explain the in vivo decreased cardiac fibrosis and improved cardiac 
function in imatinib-treated Ren2 rats. 
Recently, our group showed that inhibition of EGFR signaling also has beneficial 
effects in this model7. Therefore, it is interesting to compare the role of these 2 
growth factor receptors EGFR and PDGFRß that share tyrosine kinase activity. 
However, the effects of inhibition of either EGFR or the PDGFR differ quite 
substantially. Whereas EGF inhibition by tyrphostin decreased cardiac fibrosis, and 
also attenuated the development of LV hypertrophy (LVH), tyrphostin treatment 
did not significantly ameliorate cardiac function. In contrast, in our current 
study, although imatinib also decreased cardiac fibrosis, it failed to attenuate 
LVH, and, importantly, did improve cardiac dysfunction. Therefore, the effects of 
EGFR inhibition differ importantly from the here-described effects of inhibition 
of the PDGFRß. To analyze this discrepancy, we investigated how the PDGFRß 
transactivates the EGFR. Here, we show that when the PDGFRß is activated by its 
native ligand, PDGF, EGFR is transactivated, and this can be inhibited by imatinib. 
However, when the PDGFRß is activated by AngII, there is also concomitant 
activation of the EGFR, but this cannot be blocked by imatinib. This strongly 
suggests that AngII uses other pathways beside the PDGFRß to activate the EGFR, 
so that imatinib cannot block the effects of AngII on the EGFR. As a result, imatinib 
only blocks the PDGFRß effects in our model but not the EGFR effects. So, although 
seemingly related, EGFR or PDGFRß inhibition results in different protective effects 
in the Ren2 rat.
Given the efficacy of direct inhibition of the PDGFRß by imatinib, we propose that 
this activation of the PDGFRß is a crucial step in the development of cardiac and 
renal end-organ damage. This explains also that direct inhibition of the PDGFRß 
by imatinib is efficacious even without lowering blood pressure. Together, these 
findings implicate that imatinib attenuates the transition from LVH towards LV 
dysfunction by interrupting the AngII-induced PDGFRß activation.  
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Effects of imatinib in an AngII-driven model of accelerated nephropathy
As mentioned above, homozygous Ren2 rats experience severe hypertension 
and high levels of local tissue AngII, which together result in accelerated 
nephropathy17. We show that imatinib treatment attenuates renal damage in the 
Ren2 rat. This result is in concordance with previous studies showing the protective 
effect of PDGFR inhibition on nephropathy23,24. Previous work of de Borst et al25 
also revealed that ERK1/2 inhibition, using a mitogen-activated protein kinase 
blockade, protected against AngII-mediated renal damage. Here, we show 
combined beneficial effects of imatinib on renal parenchymal and renovascular 
level in imatinib-treated Ren2 rats.
Other studies also have demonstrated the important role for the PDGFR. Aberrant 
PDGF signaling has been implicated in various pathological conditions, such as 
oncogenesis, atherosclerosis, lung fibrosis, and kidney fibrosis26,27. Recently, Ponten 
et al showed that overexpression of PDGF-C results in dilated cardiomyopathy, 
cardiac fibrosis, and cardiac hypertrophy28, whereas PDGF-D overexpression 
activated the PDGFRß, and resulted in cardiac fibrosis29. These findings suggest that 
activation of PDGF signaling pathways plays an important role in the development 
of heart failure, in concordance with our finding of increased PDGFRß activation 
in our model. 
In conclusion, the present study is the first to demonstrate that imatinib, an orally 
active tyrosine kinase inhibitor, attenuates the development of hypertensive end-
organ damage in the hypertensive homozygous Ren2 rat, probably by inhibition of 
the AngII-related activation of the PDGFRß pathway. 
Perspectives
The findings presented in this study may have important implications for future 
treatment of cardiovascular diseases. The use of specific kinase inhibitors, already 
widely appreciated in the treatment of cancer, may also be very successful in 
cardiovascular diseases. It is known that growth factor receptors, such as the 
transforming growth factor-ß (TGFß) receptor and the EGFR, play important roles 
in the development of cardiac fibrosis and hypertrophy, and targeted inhibition 
of TGFß and EGF signaling has beneficial effects7,30. Now we also show that 
inhibition of PDGFRß signaling has beneficial effects in a model of accelerated 
LV dysfunction. Because imatinib is already clinically successfully used for cancer 
therapy, our findings suggest that strategies aimed at inhibiting such tyrosine 
kinases may help to prevent hypertensive cardiac and renal damage. 
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To the editors,
Strebhardt and Ullrich (Dec. 7 issue)1 discuss the study by Kerkelä et al., which 
suggested that imatinib is cardiotoxic1,2. However, there are controversial data on 
the role of imatinib on cardiac function that are not discussed. We published data 
showing that a reduced dose of imatinib (30 mg per kilogram of body weight per 
day) was cardioprotective in hypertensive rats3. Kerkelä et al. examined various 
doses of imatinib but showed a loss of cardiac function only at higher doses than 
those used in other studies3-5. Furthermore, clinical evidence of the cardiotoxicity 
of imatinib is circumstantial. Only 3 of 10 selected patients who received imatinib 
and subsequently had cardiac dysfunction were free of underlying cardiac disease 
or risk factors.  No detailed cardiac data are available for subjects receiving imatinib 
who did not have heart failure.
For the time being, the evidence of the clinical significance of the cardiotoxicity 
of imatinib remains thin. There is a need for studies to evaluate how frequently 
cardiotoxicity develops in patients receiving imatinib, taking into account dose 
levels of the drug, preexisting cardiac conditions, and the use of additional 
cardiotoxic drugs.  
Mark W. Schellings
Bob Löwenberg 
Yigal M. Pinto
The author replies:
There is no doubt that the kinase inhibitor imatinib has revolutionized the treatment 
of patients with chronic myeloiod leukaemia (CML). In a recent randomized study 
of 553 patients, the 5-year estimated survival rate was 89% for patients receiving 
initial imatinib therapy at a daily dose of 400 mg6. Congestive heart failure was an 
extremely rare event in this study. Other trials involving patients with CML have 
also shown that imatinib greatly improves the risk-benefit ratio6,7. The 10 patients 
described by  Kerkelä et al.2 had preexisting conditions, including hypertension in 
7 patients, diabetes in 4, and coronary artery disease in 3. Seven patients received 
elevated daily doses of imatinib (600 to 800 mg); all 10 patients had normal left 
ventricular function before treatment, and cardiac dysfunction developed after 
1 to 14 months of therapy2. Recent recommendations call for a 400-mg dose of 
imatinib as standard treatment for CML; the dose may be increased to 600 to 800 
mg if patients have a suboptimal response or if treatment fails8. Careful, long-term 
monitoring of individual patients is required to answer the question of whether 
elevated doses of imatinib substantially increase the risk of cardiotoxicity, as 
Kerkelä et al. observed in humans and mice. 
Klaus Strebhardt
Chapter 7
 113
References 
1. Strebhardt K, Ullrich A. Another look at imatinib mesylate. N Engl J Med. 
2006;355:2481-2482.
2. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, 
Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, 
Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent 
imatinib mesylate. Nat Med. 2006;12:908-916.
3. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, 
Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates 
end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. 
Hypertension. 2006;47:467-474.
4. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper 
ME. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler 
Thromb Vasc Biol. 2004;24:935-942.
5. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov 
A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental 
pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-
2821.
6. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, 
Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus 
A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes 
T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen 
JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson 
RA. Five-year follow-up of patients receiving imatinib for chronic myeloid 
leukemia. N Engl J Med. 2006;355:2408-2417.
7. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-
Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, 
Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-
Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster 
M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, 
Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib 
mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-
652.
8. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum 
F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, 
Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, 
Hehlmann R. Evolving concepts in the management of chronic myeloid 
leukemia: recommendations from an expert panel on behalf of the 
European LeukemiaNet. Blood. 2006;108:1809-1820.
Another look at imatinib mesylate
114
 
 115
Chapter 8
Discussion
General discussion and conclusions
116 Chapter 8
Despite increasing insight into the diseases that cause heart failure, it remains 
a major health problem. Cardiac remodeling is one of the changes that hallmark 
the continuous and relentless progression of left ventricular dysfunction towards 
overt heart failure. Therefore, deeper understanding of the molecular factors that 
determine cardiac remodeling are bound to yield novel opportunities to alter this 
adverse change. Recent studies have identified previously unsuspected players in 
cardiac remodeling, like matricellular proteins (chapter 2). This thesis describes the 
func-tions of several matricellular proteins during cardiac remodeling, including 
their signaling effects. In addition, it describes the potential beneficial effects of 
direct inhibition of cardiac signaling by imatinib treatment. The following paragraphs 
will discuss the presented findings, and new data on the role of other matricellular 
proteins (osteopontin, thrombospondin 1 and 2) during cardiac remodeling.
SPARC
As described for several other matricellular proteins, secreted protein acidic and 
rich in cysteine (SPARC) expression is high during development, but low during 
normal postnatal life. SPARC has been implicated in matrix remodeling during 
pathological stress, as shown by its increased expression after injury 1,2. Concerning 
the heart, increased expression has been shown after myocardial infarction (MI) 3-5 
or ß-adrenergic stimulation 6. Also, SPARC may regulate fibroblast migration after 
MI 7. In concordance with the results of Komatsubara et al., we also showed an 
increased expression of SPARC, peaking 14 days after MI (chapter 3).  Moreover, we 
investigated the function of SPARC during cardiac remodeling after MI by inducing 
MI in SPARC null and WT mice. Strikingly, almost 40% of the SPARC null mice died 
within 5 days after the induction of MI due to cardiac rupture, which indeed 
suggests an important role for SPARC in regulating matrix remodeling. Surviving 
SPARC null mice displayed aberrant infarct healing 7 and 14 days after MI, with 
deposition of a less mature collagen matrix, as shown by Sirius Red polarization. 
Also, SPARC null infarcts contained more myofibroblasts, indicating that SPARC 
indeed may regulate (myo)fibroblast migration. The abnormal wound healing in 
SPARC null mice resulted in cardiac dysfunction, as evidenced by an attenuated 
response to dobutamine. These results support the general idea that SPARC is 
involved in regulating the formation of a collagen matrix. 
The precise role that SPARC exerts is not fully identified. SPARC has been shown 
to activate transforming growth factor ß (TGFß) signaling in mesengial cells and 
fibroblasts, by binding to the TGFß receptor type II 8,9.  Since TGFß is necessary 
for early infarct healing 10, we investigated whether the lack of SPARC resulted 
in decreased SMAD2 phosphorylation, a major downstream mediator of TGFß 
signals. Indeed, we showed that SMAD2 phosphorylation was decreased after 
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TGFß stimulation in shRNA-mediated SPARC knockdown cardiac fibroblasts. This 
prompted the question whether additional TGFß could overcome the defective 
signaling in SPARC null mice, thereby protecting against cardiac rupture. Indeed, 
only 1 out of 7 SPARC KO males died due to cardiac rupture, when pretreated with 
TGFß 1 day before the onset of MI. TGFß treatment in these mice resulted in thick 
infarcts, hardly containing necrotic myocytes, suggesting an accelerated wound 
healing with increased extracellular matrix deposition. Taken together, we showed 
that the absence of SPARC resulted in an increased incidence of cardiac rupture 
after MI, probably caused by the deposition of an immature collagen matrix. Our 
data strongly suggest that defective TGFß signaling is one of the mechanisms 
involved in this defective collagen maturation. 
Syndecan-1
Syndecan-1 is a heparan sulfate proteoglycan, which contains an extracellular 
ectodomain with glycosaminoglycan chains, a transmembrane domain, and 
a short cytoplasmic tail. Syndecan-1 has been implicated as a central regulator 
of inflammation and matrix remodeling11,12, and therefore is an interesting 
candidate to play a role in cardiac remodeling. In 2004, Finsen et al. for the 
first time showed an increased expression of syndecan-1 after MI, suggesting 
a functional role during cardiac remodeling after MI 13. In chapter 4 of this 
thesis, we confirmed this upregulation, and, in addition, showed that syndecan-
1 expression after MI indeed is important to maintain cardiac function 14.
 
Syndecan-1 mRNA and protein levels increase within 4 days after MI, and reach 
their peak 7 days after MI. Seven-day-old syndecan-1 null infarcts contain more 
inflammatory cells and myofibroblasts, and have less necrotic myocytes, as 
compared to WT mice, indicating an accelerated infarct healing in these mice. 
Moreover, syndecan-1 null mice have an increased collagen deposition in the 
infarct 7 and 14 days after MI, but of an impaired quality, which may be due to an 
increased MMP activity. The accelerated infarct healing together with the altered 
deposition of immature collagen results in an increased cardiac dilatation and 
dysfunction 14 days after MI. Interestingly, adenoviral-mediated overexpression 
of syndecan-1 in WT mice resulted in an improved cardiac function as compared to 
WT mice treated with control virus. These data indicate that increased syndecan-1 
after MI might act as a barrier against inflammatory cells and also may modulate 
matrix deposition and quality. In conclusion, syndecan-1 upregulation protects 
against cardiac dilatation and dysfunction after MI. 
In chapter 5 we describe the role of syndecan-1 during hypertensive cardiac 
hypertrophy, showing that syndecan-1 null mice are protected against cardiac 
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dysfunction due to decreased cardiac fibrosis. These results were confirmed in 
vitro using short hairpin mediated knockdown of syndecan-1, and overexpression 
of syndecan-1. Stimulation with angiotensin II (AngII) or transforming growth 
factor ß (TGFß) resulted in increased protein expression of CTGF in normal 
cardiac fibroblasts, which was significantly attenuated in syndecan-1 knockdown 
fibroblasts. In contrast, overexpression of syndecan-1 resulted in an exaggerated 
CTGF expression after AngII treatment. These results clearly indicate that syndecan-
1 is able to modulate AngII induced CTGF expression, probably by acting as a co-
receptor, thereby increasing ligand-receptor affinity. 
These results are seemingly opposite to the results obtained in the MI model of 
remodeling: syndecan-1 is protective after MI, but harmful during AngII-induced 
cardiac remodeling. During wound healing after MI, syndecan-1 predominantly 
acts as a modulator of inflammation by controlling the migration of inflammatory 
cells towards the infarct area, and subsequent stages of infarct healing14. The 
increased shedding of syndecan-1 may play a crucial role herein. During AngII-
induced cardiac remodeling, we hypothesize that syndecan-1 shedding is not 
increased, and syndecan-1 rather acts as an amplifier of cellular signaling15, 
by showing that the absence of syndecan-1 decreases pro-fibrotic signaling in 
cardiac fibroblasts. Therefore, one could speculate that inhibition of syndecan-1 
only during the late phase of infarct healing might be beneficial, by decreasing the 
amount of cardiac fibrosis. In conclusion, syndecan-1 seems to have an adverse 
role in general cardiac remodeling, yet to have a beneficial role only in the acute 
phase of MI, when it limits infarct expansion. 
Osteopontin
Osteopontin (OPN) is a mulitfunctional protein expressed by various cell-
types, including macrophages and fibroblasts. OPN is highly expressed during 
embryogenesis, but its expression declines after birth, and is low in the normal, 
postnatal heart. However, OPN expression strongly increases after injury, where 
it regulates inflammatory cell migration, adhesion, and cytokine release16-18. Also, 
OPN has been implicated in the regulation of collagen deposition 19. 
Recently, several studies have been published investigating the role of OPN during 
diabetic cardiomyopathy, chronic pressure overload, angiotensin II and aldosterone 
induced cardiac remodeling 20-24. Together with the article of Trueblood and 
co-workers 25, which focused on the role of OPN after MI, these articles grossly 
describe the primary functions of osteopontin in the stressed heart. 
OPN expression is increased in the myocardium during all above-described 
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injuries, clearly indicating that OPN is involved in remodeling of the stressed heart. 
With respect to MI, OPN mRNA strongly increases in the infarct region three days 
after MI, and is still modestly increased 28 days after MI. OPN null mice develop 
exaggerated left ventricular dilation after MI due to a defect in collagen synthesis, 
implicating an important role for OPN in post-MI remodeling 25. Decreased 
collagen deposition in OPN null mice also has been demonstrated after AngII 
infusion, and aldosterone infusion 22-24. In these models, the decrease in fibrosis 
was associated with a decreased cardiac function in OPN KO mice. Especially for 
the AngII and aldosterone model this is surprising, since cardiac fibrosis is thought 
to have detrimental effects on cardiac function. Interestingly, no difference in 
fibrosis was found after chronic pressure overload between OPN WT and KO mice 
21. Moreover, left ventricular hypertrophy was attenuated in OPN KO mice after 
aortic banding compared to WT mice, a phenomenon which was not present 
after AngII or aldosterone treatment. This strongly suggests that OPN may exert 
different functions during mechanical and neurohormonal hypertension. 
In conclusion, the upregulation of OPN in the stressed heart is necessary to 
regulate collagen deposition, thereby preventing cardiac dilation. 
Thrombospondin 1 & 2
Thrombospondins (TSPs) are extracellular glycoproteins, and exert their function 
by binding to membrane proteins or cytokines, thereby regulating the structure 
of the extracellular matrix and cell function26. As for other matricellular proteins, 
their expression is high during embryogenesis, but declines after birth 27,28. 
Recently, Frangogiannis et al. showed that TSP1 prevents expansion of healing 
myocardial infarcts 29. First, they showed that ischemia increases TSP1 mRNA and 
protein. Lack of TSP1 increases transcript levels of several cytokines, and presence 
of macrophages and myofibroblasts in the infarct zone, as well as in remote, 
non-infarcted myocardium. This suggests that TPS1 null mice have an increased 
inflammatory response after ischemia-reperfusion, which correlated with an 
increased infarct expansion. Also, TSP1 is known to be an activator of TGFß, an 
important regulator of post-MI remodeling. Indeed, TSP1 null mice showed a 
tendency to a decreased phosphorylation of SMAD2, a known mediator of TGFß 
signaling, which in part could explain the altered myocardial remodeling after 
MI in these mice. Since TSP1 is selectively expressed in the infarct border zone, 
it might control infarct remodeling, by protecting the non-infarcted zone from 
remodeling 29. The role of TSP1 in chronic pressure overload or angiotensin II 
mediated hypertension has not been studied to date, although this may be very 
interesting, since TSP1 is a potent activator of TGFß, as mentioned above. In fact, 
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Zhou et al. showed that TSP1 is an important mediator of angiotensin II-induced 
TGFß activation 30. Angiotensin II stimulated TGFß activity in rat cardiac fibroblasts 
was totally blocked when they were co-treated with TSP1 neutralizing antibodies 
or TSP1 antagonistic peptides. Therefore, it would be interesting to see whether 
this is also the case in an in vivo setting. 
With respect to TSP2, our group has shown that TSP2 is upregulated in hypertrophic 
hearts that are prone to fail, and that lack of TSP2 results in cardiac rupture or 
severe cardiac dysfunction after AngII infusion 31. Interestingly, TSP2 null mice 
do not display any cardiac abnormalities at baseline. The mechanism behind the 
increased cardiac rupture and dysfunction in TSP2 null mice after AngII infusion 
was suggested by the exaggerated activation of matrix metalloproteinase (MMP) 
2 and 9 in these mice. It is known that TSP2 is capable of binding proMMP2 and 
MMP2, which than may be endocytosed via the LRP1 receptor 32. Lack of TSP2 would 
therefore result in an uncontrolled activation of MMP2 and MMP9, contributing 
to the disorganization of the matrix, as seen in TSP2 null mice. 
Taken together, TSP1 and TSP2 have important roles in cardiac remodeling. Lack of 
these proteins disturbs the normal inflammatory response or weakens the cardiac 
matrix, thereby accelerating cardiac dysfunction after injury.
Matricellular proteins as extracellular mediators of intracellular 
signal transduction 
Matricellular proteins perform various functions during wound healing, as 
described above, but one of the most intruiging is their ability to modulate outside-
in cellular signaling. Matricellular proteins seem to be fine-tuners of cellular 
signaling, thereby optimizing the signal brought to the cell by either increasing 
ligand-receptor affinity or increasing the amount of ligands presented to the 
receptor. For instance, SPARC, Syndecan-1, and TSP-1 have been shown to modulate 
TGFß signaling through different ways. While SPARC increases the ligand-receptor 
affinity, Syndecan-1 may increase the amount of ligand presented to the receptor. 
Additionally, TSP-1 is involved in the activation of TGFß. This shows that matricellular 
proteins are involved in various steps of signal transduction, which is one of the 
mechanisms by which they control wound healing. The importance of knowing 
crucial signal transduction pathways involved in the progression of a disease is 
immense. Recently, drugs inhibiting the activity of specific signal transduction 
proteins have been developed. One of these drugs is imatinib mesylate, which is 
successfully used to treat patients with chronic myeloid leukemia (CML).  Imatinib 
blocks the constant tyrosine kinase activity of the fusion protein bcr/abl, thereby 
neutralizing the molecular defect that causes CML. Since imatinib is also able to 
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block the activity of the platelet-derived growth factor receptor, a receptor known 
to be involved in cardiovascular disease, we investigated whether imatinib also is 
useful for the treatment of cardiovascular diseases, like hypertension.
Imatinib as a possible anti-fibrotic agent
In chapter 6 of this thesis, we describe the potential beneficial effects of imatinib 
treatment, especially its ability to inhibit cardiac fibrosis during hypertension. 
Our findings with respect to the anti-fibrotic properties of imatinib are confirmed 
in many other tissues, like liver, lung, and skin 33-35. These studies all suggest 
that imatinib is a well-fit candidate for clinical trials examining its anti-fibrotic 
properties. However, recently Kerkelä et al. suggested that imatinib may have 
cardiotoxic effects 36.  They describe ten patients who developed heart failure 
after the initiation of imatinib treatment. However, only three were devoid of 
cardiac disease or risk factors. Therefore, their data cannot establish the claimed 
‘imatinib-induced heart failure’ as suggested in their discussion. Also, they only 
showed a decreased cardiac function after administration of the highest dose of 
imatinib (200 mg/kg/day), being reasonably high as compared to other animal 
studies. A large-scale animal study investigating the cardiac effects of a long-
term administration of different doses of imatinib should be conducted to provide 
answers regarding the potential cardiotoxicity of imatinib. Meanwhile, patients 
taking imatinib should be closely monitored with respect to cardiac function.
Table 1: Cardiac phenotypes of several matricellular protein null mice after myocardial infarction (MI) or angiotensin II 
(AngII) infusion.
Matricellular 
protein
Cardiac phenotype after MI
Cardiac phenotype after
AngII infusion
References
Osteopontin Exaggerated LV dilatation Decreased cardiac fibrosis 22,23,25
SPARC Increased incidence of
cardiac rupture
No studies
TSP1
Exaggerated post-MI 
remodeling
No studies
29
TSP2 Increased incidence of
cardiac rupture
Increased LV dysfunction 
and cardiac rupture
31,37
Syndecan-1 Decreased cardiac fibrosis 14
Discussion
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Matricellular proteins are crucial regulators of cardiac 
remodeling; implications of the presented findings
The summary of cardiac phenotypes in SPARC, syndecan-1, osteopontin, TSP1 and 
TSP2 null mice as presented above clearly shows that these proteins play crucial 
roles when the myocardium is subjected to (hemodynamic) stress (table 1).  All 
these proteins are members of the family of matricellular proteins, an evolving 
family of proteins, which have the ability to regulate cell-matrix interactions. 
Strikingly, none of the respective null mice display any cardiac abnormalities at 
baseline. However, after MI, the lack of matricellular proteins induces an evident 
phenotype. This is indicated by the increased incidence of cardiac rupture, increased 
cardiac dilatation, and increased cardiac dysfunction in comparison to WT mice, 
as described in this thesis. A shared phenotype seen by these matricellular protein 
null mice is their inability to produce a collagen matrix of adequate quality. The lack 
of matrix quality may be present under baseline conditions, but does not seem to 
influence normal cardiac performance. In contrast, defective collagen maturation 
in the infarct scar seems to be a very important cause for the phenotypes described 
in this thesis. 
Apart from their ability to influence collagen maturation, matricellular proteins 
also influence intracellular signaling. For instance, both loss of SPARC and 
syndecan-1 decreases phosphorylation of SMAD2. Finally, several matricellular 
proteins are able to control the inflammatory response, possibly through the 
above effects on intracellular signaling, thereby allowing cardiac remodeling 
in the infarct scar, but protecting the healthy, non-infarcted myocardium from 
infiltrating inflammatory cells. This especially is the case for TSP1 and syndecan-
1, since the TSP1 null mice display infarct expansion with increased numbers of 
inflammatory cells invading in the healthy myocardium, and syndecan-1 null mice 
show an increased abundance of inflammatory cells after MI. 
Matricellular proteins as biomarkers
The findings described in this thesis have important implications for the prevention 
and treatment of heart failure. Recently, serum syndecan-1 has been identified as 
a marker of poor prognosis in myeloma patients, and inhibition of syndecan-1 is 
a viable target for myeloma treatment38. Whether serum syndecan-1 levels are 
correlated with the severity of heart disease remains to be determined. Based on 
our results, serum syndecan-1 levels may be a biomarker for the inflammatory 
response after MI, whereas syndecan-1 inhibition might be beneficial during 
hypertension by blocking the development of cardiac fibrosis. SPARC seems to act 
as a biomarker for melanoma, as increased SPARC and glypican-3 serum levels 
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can detect early stage melanoma39. Moreover, high levels of SPARC were found in 
the blood of patients with severe heart failure, and used as a marker of platelet 
activation40. The increased serum levels of SPARC may not only indicate platelet 
activation, but also ongoing cardiac remodeling, as we showed increased SPARC 
expression after MI. 
Genetic variation in matricellular proteins
Since we showed that SPARC expression is crucial during wound healing after 
MI, this protein is an attractive target for clinical investigation regarding infarct 
healing. For instance, SPARC mutations may cause impaired wound healing, 
resulting in decreased cardiac function or even cardiac rupture. Indeed, SPARC 
mutations can influence collagen binding41,42, which may lead to decreased 
collagen quality. Therefore, screening for SPARC mutations could be of benefit, by 
possibly predicting adverse cardiac remodeling. Based on our results, syndecan-
1 mutations could lead to an altered inflammatory response after injury, which 
may lead to impaired wound healing, and subsequent cardiac failure. On the 
other hand, mutated syndecan-1 may also have implications on the development 
of cardiac fibrosis during hypertension. Currently, no reports are available linking 
syndecan-1 mutations with cardiovascular diseases.
In conclusion, our recent efforts in unraveling the role of matricellular proteins 
during cardiac remodeling have yielded important new insights. These novel 
concepts on the cardiac role of matricellular proteins can trigger clinical research 
investigating the correlation between the quality of the cardiac matrix and 
the development of heart failure after MI, or during hypertension. In addition, 
we have shown that matricellular proteins are important modulators of signal 
transduction, and that drugs inhibiting specific signaling pathways are useful in 
the treatment of cardiovascular disease, with matricellular proteins as potential 
new therapeutic targets.
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Summary
Myocardial infarction (MI) and chronic hypertension are two main risk factors 
for the development of heart failure, a disease that represents a major cause of 
mortality and morbidity in the Western world. Although treatment of MI and 
hypertension is improving, there is still need to gain more insight into the changes 
occuring in the heart due to these diseases. Recently, a new group of extracellular 
matrix proteins, the matricellular proteins, has been implicated in the regulation 
of wound healing. This thesis describes the role of a subset of matricellular 
proteins in the injured heart, and shows the anti-fibrotic properties of imatinib, an 
already clinically used anti-cancer drug. Overall, this thesis adds new knowledge 
regarding cardiac remodeling after MI or during hypertension, which may improve 
treatment of cardiac diseases. 
In chapter 2, available literature on the function of matricellular proteins in the 
stressed heart is summarized. It discusses the potential roles of the matricellular 
proteins tenascin C, tenascin X, thrombospondin 1, thrombospondin 2, secreted 
protein acidic and rich in cysteine (SPARC), and osteopontin in the stressed heart. 
Today, several questions regarding the role of these proteins in the injured heart 
are answered and discussed in chapter 8.
Chapter 3 describes the function of the matricellular protein SPARC after MI. First, 
we show that SPARC protein expression is increased 3 days after MI, while peaking 
14 days after MI. Strikingly, the absence of SPARC resulted in a significantly increased 
mortality after MI, due to cardiac rupture. Additionally, surviving SPARC KO mice 
have an impaired response to hemodynamic stress, as compared to wild-type 
mice. These features may be the consequence of the deposition of less qualitative 
collagen in the infarcts of SPARC KO mice, as shown by Sirius Red polarization. 
Also, MMP activity is increased in SPARC KO infarcts. In addition, TGFß signalling 
was impaired in SPARC knockdown fibroblasts, confirming SPARC as a modulator 
of TGFß signalling. Infusion of TGFß in SPARC KO animals improved survival after 
MI by preventing cardiac rupture. These findings show the crucial role of SPARC in 
regulating infarct healing through its effects on collagen maturation as well as on 
intracellular signalling.
In chapter 4, the function of the matricellular protein syndecan-1 after MI 
is described. Syndecan-1 expression readily increases after MI, reaching its 
maximum 7 days post-MI. The inflammatory response after MI was severely 
increased in syndecan-1 KO mice, resulting in an accelerated removal of necrotic 
cardiomyocytes, and replacement by granulation tissue. This was confirmed 
in vitro, by showing increased adhesion and transmigration of syndecan-1 KO 
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inflammatory cells. The increased inflammation and accelerated wound healing 
in syndecan-1 KO mice resulted in increased collagen deposition, but of impaired 
quality, which is related to increased matrix metalloproteinase activity. Together, 
this resulted in cardiac dilatation and dysfunction in syndecan-1 KO mice after 
MI. In contrast, syndecan-1 overexpression in WT mice decreased inflammation, 
and improved the quality of collagen deposition, resulting in an improved cardiac 
function. This study reveals an important role for syndecan-1 in mediating cardiac 
healing after MI. 
The importance of syndecan-1 as a modulator of cardiac remodelling was confirmed 
in a model of chronic hypertension, as described in chapter 5. Importantly, lack of 
syndecan-1 is beneficial in this model of cardiac stress, by decreasing the amount of 
cardiac fibrosis. The direct involvement of syndecan-1 in profibrotic signalling was 
confirmed in vitro. Knockdown of syndecan-1 in cardiac fibroblasts significantly 
attenuated the expression of the profibrotic protein connective tissue growth 
factor (CTGF) after angiotensin II of TGFß stimulation, whereas overexpression 
of syndecan-1 increased CTGF expression. Therefore, syndecan-1 might be a new 
therapeutic target for decreasing cardiac fibrosis during hypertension.
After investigating the modulatory role of matricellular proteins on intracellular 
signalling, we addressed the importance of intracellular signalling in the 
development of cardiac fibrosis more directly in chapter 6. Imatinib, a successful 
anti-cancer drug, directly inhibits the kinase activity of the platelet-derived 
growth factor receptor-ß. Hypertensive homozygous Ren2 rats treated with 
imatinib developed less cardiac fibrosis than placebo-treated Ren2 rats, which 
was accompanied by a better cardiac function. Also, kidneys of Ren2 rats were 
protected by imatinib treatment. The anti-fibrotic properties of imatinib were 
confirmed in vitro. The clinical implications of these results are highlighted in 
chapter 7. 
In conclusion, this thesis describes the importance of matricellular proteins 
during cardiac remodeling after MI or during hypertension. It also highlights the 
potential of matricellular proteins to influence intracellular signalling, and shows 
that specific inhibition of signalling pathways has beneficial effects. This newly 
obtained knowledge increases our insight in the development of these diseases, 
which may have important therapeutic implications.  
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Samenvatting
Het krijgen van een hartinfarct en chronische hypertensie zijn twee belangrijke 
risicofactoren voor de ontwikkeling van hartfalen, een ziekte die een grote oorzaak 
is van mortaliteit en morbiditeit in de westerse wereld. Hoewel de behandeling 
van een hartfinfarct en hypertensie steeds beter wordt, is het nog steeds nodig 
om meer inzicht te krijgen in de veranderingen die door deze ziekten optreden in 
het hart. Recentelijk is aangetoond dat een nieuwe groep extracellulaire matrix 
eiwitten, de matricellulaire eiwitten, betrokken is bij de regulatie van wondheling. 
Dit proefschrift beschrijft de rol van enkele matricellulaire eiwitten in het zieke 
hart en toont aan dat imatinib, een geneesmiddel tegen kanker dat al in de 
kliniek gebruikt wordt, anti-fibrotische eigenschappen heeft. Dit proefschrift 
voegt nieuwe kennis toe over cardiale remodelering na een hartinfarct of tijdens 
chronische hypertensie, waardoor de behandeling van deze ziekten verbeterd kan 
worden.
In hoofdstuk 2 wordt de beschikbare literatuur over de functie van matricellulaire 
eiwitten in het zieke hart samengevat. De potentiële functies van de matricellulaire 
eiwitten tenascin C, tenascin X, thrombospondin 1, thrombospondin 2, secreted 
protein acidic and rich in cysteine (SPARC) en osteopontin in het zieke hart worden 
ook besproken. Verschillende vragen omtrent de functie van deze eiwitten in het 
zieke hart zijn inmiddels beantwoord en worden besproken in hoofdstuk 8.
Hoofdstuk 3 beschrijft de functie van het matricellulaire eiwit SPARC na een 
hartinfarct. Om te beginnen tonen we aan dat de eiwitexpressie van SPARC toe-
neemt 3 dagen na het infarct en maximaal is op dag 14 na het infarct. De afwezigheid 
van SPARC zorgt voor een toename van de mortaliteit na een hartinfarct, veroorzaakt 
door een toename in cardiale ruptuur. Ook vertonen overlevende SPARC KO muizen, 
vergeleken met wildtype muizen, een gebrekkige respons op hemodynamische 
stress. Deze zaken kunnen het gevolg zijn van de depositie van minder kwalitatief 
collageen in het infarctgedeelte van de SPARC KO muizen, zoals we aantonen 
met Sirius Rood polarisatie. Ook de activiteit van MMP’s is verhoogd in de SPARC 
KO infarcten. SPARC knockdown fibroblasten vertoonden een verminderde TGFß 
signalering, daarmee bevestigend dat SPARC een modulator van TGFß signalering 
is. Infusie van TGFß in SPARC KO dieren verbeterde de overlevingskansen na een 
infarct door cardiale ruptuur te voorkomen. Samen laten deze bevindingen zien 
dat SPARC een cruciale rol speelt in de regulatie van infarctheling door zijn effecten 
op collageenmaturatie en intracellulaire signalering.
In hoofdstuk 4 wordt de functie van het matricellulaire eiwit syndecan-1 na 
een hartinfarct beschreven. De expressie van syndecan-1 neemt snel toe na een 
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infarct en piekt na 7 dagen. De inflammatoire respons na een hartinfarct was 
ernstig verhoogd in syndecan-1 KO muizen, resulterend in een versnelde ruiming 
van necrotische cardiomyocyten en vervanging door granulatieweefsel. Deze 
bevindingen werden in vitro bevestigd door verhoogde adhesie en transmigratie 
aan te tonen in syndecan-1 KO inflammatoire cellen. De verhoogde inflammatie 
en versnelde wondheling in syndecan-1 KO muizen resulteerde in een verhoogde 
depositie van collageen, maar van een slechtere kwaliteit, wat is gerelateerd aan de 
verhoogde matrix metalloproteinase activiteit in syndecan-1 KO infarcten. Samen 
zorgden deze veranderingen voor cardiale dilatatie en dysfunctie in syndecan-1 
KO dieren na een hartinfarct. Tegenovergesteld zorgde syndecan-1 overexpressie 
in WT muizen voor een verlaagde inflammatie en een betere collageen kwaliteit, 
resulterend in een verbeterde cardiale functie. Deze studie laat een belangrijke rol 
zien voor syndecan-1 in de regulatie van wondheling na een hartinfarct.
Het belang van syndecan-1 als een modulator van cardiale remodelering werd 
bevestigd in een model van chronische hypertensie, zoals beschreven in hoofdstuk 
5. Interessant genoeg is het missen van syndecan-1 juist goed in dit model 
van cardiale stress door het verminderen van de hoeveelheid cardiale fibrose. 
De directe betrokkenheid van syndecan-1 in profibrotische signalering werd 
bevestigd in vitro. Syndecan-1 knockdown in cardiale fibroblasten verminderde 
de expressie van het profibrotische eiwit connective tissue growth factor (CTGF) 
significant na angiotensine II of TGFß stimulatie, terwijl overexpressie van 
syndecan-1 CTGF expressie verhoogde. Deze resultaten tonen aan dat syndecan-1 
een nieuw therapeutisch doel kan zijn om de ontwikkeling van cardiale fibrose te 
verminderen tijdens hypertensie.
Na de modulerende rol van matricellulaire eiwitten op intracellulaire signalering 
hebben we het belang van intracellulaire signalering in de ontwikkeling van 
cardiale fibrose meer direct bestudeerd in hoofdstuk 6. Imatinib, een succesvol 
medicijn tegen kanker, blokkeert specifiek de kinase activiteit van de platelet-
derived growth factor receptor-ß (PDGFR-ß). Hypertensieve homozygote Ren2 
ratten die behandeld werden met imatinib ontwikkelden minder cardiale fibrose 
dan Ren2 ratten met een controle behandeling en hadden ook een betere cardiale 
functie. Ook beschermde behandeling met imatinib tegen nierschade in de Ren2 
ratten. De antifibrotische eigenschappen werden bevestigd in vitro. De klinische 
implicaties van deze resultaten worden belicht in hoofdstuk 7.
Concluderend beschrijft dit proefschrift het belang van matricellulaire eiwitten 
tijdens cardiale remodelering na een hartinfarct of tijdens hypertensie. 
Daarnaast benadrukt dit proefschrift de potentie van matricellulaire eiwitten om 
intracellulaire signalering te beinvloeden en toont aan dat specifieke remming 
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van PDGFR-ß een gunstig effect heeft. Deze nieuw verkregen kennis vergroot 
ons inzicht in de ontwikkeling van deze ziekten en kan daarom belangrijke 
therapeutische implicaties hebben.  
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Dankwoord
Een proefschrift komt tot stand door vele mensen, zeker niet alleen door de 
schrijver ervan. Daarom wil ik op deze plaats alle mensen bedanken die aan dit 
boekwerk hebben bijgedragen.
Professor Doctor Pinto, beste Yigal. Ik kan me nog als de dag van gisteren herinneren 
dat ik ietwat zenuwachtig de staf Cardiologie binnenliep, wachtend op toen nog 
dr. Pinto. De zenuwen verdwenen meteen toen jij, enthousiast als altijd, over het 
toenmalige onderzoek begon te vertellen. Je hebt de klasse om altijd alles positief 
in te zien en mensen te enthousiasmeren voor klinisch dan wel basaal onderzoek. 
Daarnaast ben je ook nog een man van de wereld, waarmee je de hele avond kunt 
praten over totaal uiteenlopende zaken. Van een ding heb je echter iets minder 
verstand, en gelukkig ben ik daarin in ieder geval de bovenliggende partij geweest 
de afgelopen jaren. Ik wil je van harte bedanken voor alle steun in de afgelopen 
jaren en ik hoop dat we samen nog mooie dingen kunnen verwezenlijken. 
Dr. Heymans, beste Stephane, jij bent zeker de mede-initiator van dit proefschrift. 
In de zomer van 2003 kwam je je voorstellen tijdens onze ‘traditionele’ barbecue 
bij Yigal, met de nu vanzelfsprekende champagne. Ondertussen had ik via de mail 
al veel met je te maken gehad, ik had namelijk de taak om al jouw KO muizen 
de CPV binnen te loodsen, wat natuurlijk een uitgelezen kans was voor mij om 
kennis te maken met de matricellulaire eiwitten. Tijdens mijn onderzoeken vroeg 
je altijd geinteresseerd naar de gang van zaken en gaf je nuttige tips. Jouw kennis 
van histologie en proefdieronderzoek is van groot belang voor ons lab. Hartelijk 
bedankt voor de fijne jaren!
Rick van Leeuwen: Westernblotkoning, celcultuurprins, beursgorilla, vinoloog, 
achtergronddanser van Re-play, ex-ploeggenoot van Rene van der Gijp! 
Woorden schieten te kort om jouw rol in ons lab aan te geven. Labmentor en 
cultuurbewaarder komen het dichtst in de buurt, denk ik. Altijd kritisch op de 
resultaten en nooit te beroerd om zelf mee te denken, heb je een groot aandeel 
gehad in de totstandkoming van dit proefschrift. Ik ben er trots op dat je mijn 
paranimf bent. Mijn dank is groot!
Rudy Duisters: kloneringskoning, Brabander en PSV’er! Vanaf dag 1 zat het snor 
tussen ons, het is goed om iemand te hebben die tijdens de lunch het meestal 
met je eens is! Ik heb je waarschijnlijk helemaal gek gemaakt met mijn vele 
vragen, maar gelukkig kon/kun je daar goed tegen. De laatste jaren ben je zelf 
meer onderzoek gaan doen en met jouw kwaliteiten moet daar zeker iets goeds 
uitkomen!
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Mirjam van Loon (West-Brabander), de vele uren die je samen met mij en voor mij 
op het muizenlab van farmacologie hebt doorgebracht staan aan de basis van dit 
proefschrift! Heel veel dank daarvoor! Ook heb je aan het begin gestaan van alle 
IHC protocollen, nu mooi geordend op onze share. Kortom, jouw bijdrage aan dit 
proefschrift is levensgroot! Na een aantal jaren in ons lab ging je je eigen weg om 
te gaan studeren in Utrecht. Ik wens je hierbij heel veel succes! 
Blanche Schroen, Blanchie Panchie. Ik ben er trots op dat ik jouw opvolger mag zijn. 
Je hebt met jouw prachtige proefschrift een standaard gezet, waaraan iedereen 
zich op kan trekken. Je bent natuurlijk mijn eigenlijke congresmaatje en ik zal 
onze belevenissen in the States nooit meer vergeten. Van de merlot met nachos in 
Orlando naar shots in New Orleans tot en met Toto in Chicago, bedankt voor alle 
gezelligheid! Tegen de tijd dat ik promoveer, heb jij Londen al veroverd! Veel succes 
met al wat komen gaat! 
Geert van Almen, weer een Brabander! Lang, heel lang, heb ik tegen je aan 
moeten zeuren om toch maar eens bij ons in het lab te komen kijken voor een 
eventuele stageplaats tijdens je studie gezondheidswetenschappen. Maar ik hoop 
(en denk) dat je het uiteindelijk wel hebt gewaardeerd. Na een fantastische stage 
als ‘Tweezerman’ ben je nu gepromoveerd tot AiO binnen onze groep. Je houdt 
je nu bezig met de meest evidente vraag in de wereld; hoe veroudert een hart? 
Ik weet zeker dat hieruit mooie publicaties zullen volgen! Geert, jouw humor en 
langdradigheid zijn ongeëvenaard! Bedankt voor alles en we zullen elkaar nog 
vaak treffen in de toekomst! 
Joost Leenders: mede-student & wielrenner, halve Brabander, overbuurman! Ik 
denk dat je de meest sociale kerel bent op het oostelijk halfrond (en dus ook op 
het westelijk)! Je bent de cel-isolatiekoning van ons lab en hebt verder prachtige 
resultaten behaald met KLF15. Daarnaast ben je ook een cruciale factor in het 
slagen van een lab-uitje! Befaamd zijn jouw woorden: “Ik ga het niet te laat maken 
vanavond”, om vervolgens iedereen op sleeptouw te nemen en er een geweldige 
avond van te maken! Joost, ook jij heel veel succes in de toekomst! 
N.A.R.D. Kubben, the man with the plan. Hoe kan een Limburgse jongen overleven 
tussen al dat Brabantse geweld? Nard doet het al 3 jaar met verve! Nard, jouw 
experimenten zijn grotesk en nu al een begrip in het EMC lab. Binnenkort worden 
ze uitbetaald in prachtige artikelen! En natuurlijk kan ik hier de befaamde 
rabarberchampagne uit Munstergeleen niet onbenoemd laten, een onmisbaar 
onderdeel van onze AiO-uitjes. 
Melissa en Davy, the Leuven connection. Jullie verdienen samen een meer dan 
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eervolle vermelding in dit dankwoord! Mede dankzij jullie inzet zijn er een paar 
mooie artikelen verschenen. Naast onze samenwerking hebben jullie zelf ook 
prachtige resultaten met andere projecten. Hartelijk bedankt voor alles!
Esther Creamers! Vanuit Dallas, TX, ben je ons lab binnengevlogen als een ware 
wervelwind. Samen met Joost en Viola terroriseer je de labtafels en pipetten, op 
zoek naar nieuwe data. Je enthousiasme werkt aanstekelijk op de hele groep. Of de 
hierboven genoemde eigenschappen het gevolg zijn van overmatig koffiegebruik 
laat ik in het midden...In ieder geval bedankt voor alles en nog veel succes hier in 
het EMC lab!
Terwijl u dit dankwoord aan het lezen bent, kunt u zich vast niet voorstellen dat 
ons EMC lab in 2003 nog maar uit 7 mensen bestond. En dan te bedenken dat er 
nog wat namen aankomen! Laat ik verdergaan met iemand die heel veel goed 
werk heeft afgeleverd en mede daardoor een baan binnen ons lab heeft verdiend. 
Gonda, bedankt voor alle Westerns en Q-PCR’s die je hebt verricht en ik ben blij dat 
je nog steeds in onze groep zit. Verder wil ik ook de drie kroonprinsen Kevin ‘kef-
kef’, Wouter en Frank ‘bonobo’ bedanken voor al het werk! Ook jullie zullen nog 
terugkeren in het warme nest van het EMC lab. Viola, de stille kracht, keep up the 
good work! Arie, als bioinformaticus creëer  je steeds weer nieuwe targets voor 
het lab, hiermee maak je je onmisbaar. Succes met je promotie!  Verder wil ik ook 
de mensen van het eerste uur bedanken, Suzanne, Sara, Umesh en Jop. Bedankt 
voor alle steun in de eerste jaren op het EMC lab. Ook de secretaresses van de 
vakgroep Cardiologie kan ik niet onvermeld laten! Bianca, Barbara en de overigen, 
heel erg bedankt voor alles! 
Ik wil de leden van de leescommissie hartelijk bedanken voor het beoordelen van 
mijn proefschrift, in het bijzonder de voorzitter van de leescommissie prof. dr. 
Harry Crijns. U heeft altijd interesse getoond voor het onderzoek in het lab ‘aan 
de overkant’. Ik wil u hiervoor hartelijk bedanken en vind het een eer dat u de 
voorzitter van mijn leescommissie was.    
Tijdens mijn promotie-onderzoek heb ik niet alleen in het lab van Cardiologie 
gezongen, maar ook diverse andere laboratoria hebben van mijn zangkunsten 
kunnen genieten. Een heel bijzonder woord van dank gaat uit naar de medewerkers 
van het dierenlab van Farmacologie: Jacques, Agnieszka, Peter, Helma, Nicole. Zij 
stonden altijd klaar wanneer ik in de problemen raakte. Vooral Jacques en Agnieszka 
hebben mij de fijne kneepjes van het dierenwerk bijgebracht en stonden altijd klaar 
om toch nog wat extra dieren in te zetten voor een bepaalde studie. Mijn dank is 
groot!  Ook de leden van onze ‘dinsdagochtendclub’ wil ik van harte bedanken 
voor alle vruchtbare ontmoetingen en alle hulp die zij hebben geboden. Tijdens 
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deze bijeenkomsten op dinsdagochtend ontmoet je als AiO ook collega-AiO’s van 
andere vakgroepen, sommigen hiervan KAN ik eenvoudigweg niet onbenoemd 
laten. Pascal Smeets, onze proefballonnetjes over de toekomst van België zal ik 
nooit vergeten. Bedankt voor alle fibroblasten die je mij schonk (ook dank aan 
Birgit hiervoor!). Susanne en Veerle, tja...eigenlijk zijn jullie geen Farmaco-AiO’s 
maar Cardio-AiO’s! Bedankt voor alle gezelligheid! Rest mij om jullie veel succes 
te wensen met het schrijven van jullie proefschrift. De mensen van de vakgroep 
Pathologie wil ik bedanken voor hun gastvrijheid en hulp de afgelopen jaren. 
Veronica, als ex-cardio verdien je natuurlijk een speciaal plaatsje in dit dankwoord, 
bedankt voor de prachtige ISH. Ook Jack nogmaals bedankt voor het verhelpen 
van de vele microscoopproblemen. Bij de vakgroep Anatomie & Embryologie kon 
ik altijd terecht voor het nodige snijwerk, hartstikke bedankt hiervoor. Verder wil 
ik de mensen van de CPV ontzettend bedanken voor alle hulp die ik in de afgelopen 
jaren heb gekregen! Natuurlijk mag ik onze buren van Fysiologie niet vergeten, zij 
hebben namelijk nog het meeste last van de voortdurende Cardio-terror. Peter en 
consorten, beter een goede buur is hier helemaal op zijn plaats, bedankt!
Dr. Martin Götte and Dr. Helene Sage, thank you very much for your cooperation on 
the syndecan-1 and SPARC projects, respectively. 
Zonder ontspanning geen inspanning! Hein, bedankt dat je mijn paranimf wilt 
zijn! Je hebt het Zuiden verlaten voor Amsterdam. Maar de lokroep van het ware 
bourgondische leven, waar jij goed bekend mee bent, zal niet lang op zich laten 
wachten…. Verder wil ik natuurlijk Randy, Jacco, Jeroen, Jacques, Henk, Jaro en alle 
(oud-)Heeren van Abraxas, BMC6 en alle anderen niet vergeten. Bedankt voor alles 
en ik hoop nog veel plezier met jullie te hebben in de toekomst. 
Ik wil mijn familie bedanken voor de niet aflatende interesse en steun die ik de 
afgelopen jaren heb gekregen. Pap en mam, jullie hebben ervoor gezorgd dat ik 
niets tekort kwam en hebben mij altijd gesteund. Het is altijd heerlijk om weer 
thuis te komen! Frank, van twee broers moet er een de technicus zijn en dat ben 
jij! Ik ben trots op alles wat je doet!
Marjolein: I can’t stop loving you! Jij weet precies welke melodie hierbij hoort. De 
afgelopen jaren was je mijn steun en toeverlaat, mijn rustpunt, maar bovenal mijn 
meisje! En ik hoop dat dat nog lang zo mag blijven!
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